WO2021073197A1 - Composition containing lactic acid bacteria and use thereof - Google Patents
Composition containing lactic acid bacteria and use thereof Download PDFInfo
- Publication number
- WO2021073197A1 WO2021073197A1 PCT/CN2020/105229 CN2020105229W WO2021073197A1 WO 2021073197 A1 WO2021073197 A1 WO 2021073197A1 CN 2020105229 W CN2020105229 W CN 2020105229W WO 2021073197 A1 WO2021073197 A1 WO 2021073197A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- parts
- composition
- lactobacillus
- strain
- stachyose
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 129
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 92
- 241000894006 Bacteria Species 0.000 title claims abstract description 53
- 239000004310 lactic acid Substances 0.000 title claims abstract description 47
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 46
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 42
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 42
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 42
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 42
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 42
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 42
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 42
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 39
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 39
- 229920002261 Corn starch Polymers 0.000 claims abstract description 38
- 229920001353 Dextrin Polymers 0.000 claims abstract description 38
- 239000004375 Dextrin Substances 0.000 claims abstract description 38
- 239000008120 corn starch Substances 0.000 claims abstract description 38
- 235000019425 dextrin Nutrition 0.000 claims abstract description 38
- 229920001202 Inulin Polymers 0.000 claims abstract description 36
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 36
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 36
- 229940029339 inulin Drugs 0.000 claims abstract description 36
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 36
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 35
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 35
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 21
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims abstract description 21
- 229960001243 orlistat Drugs 0.000 claims abstract description 21
- 229940079593 drug Drugs 0.000 claims abstract description 19
- 208000004998 Abdominal Pain Diseases 0.000 claims abstract description 15
- 206010000060 Abdominal distension Diseases 0.000 claims abstract description 13
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 12
- 230000000968 intestinal effect Effects 0.000 claims abstract description 8
- 206010010774 Constipation Diseases 0.000 claims abstract description 6
- 229940099112 cornstarch Drugs 0.000 claims abstract description 4
- 239000000843 powder Substances 0.000 claims description 58
- 238000002360 preparation method Methods 0.000 claims description 50
- 235000013399 edible fruits Nutrition 0.000 claims description 35
- 235000013305 food Nutrition 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 239000002775 capsule Substances 0.000 claims description 11
- 239000000853 adhesive Substances 0.000 claims description 9
- 230000001070 adhesive effect Effects 0.000 claims description 9
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 8
- 240000009088 Fragaria x ananassa Species 0.000 claims description 8
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 5
- 240000001717 Vaccinium macrocarpon Species 0.000 claims description 5
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 claims description 5
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 claims description 5
- 206010000059 abdominal discomfort Diseases 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 5
- 235000004634 cranberry Nutrition 0.000 claims description 5
- 229940045731 elderberry fruit Drugs 0.000 claims description 5
- 230000005176 gastrointestinal motility Effects 0.000 claims description 5
- 230000008991 intestinal motility Effects 0.000 claims description 5
- 230000003870 intestinal permeability Effects 0.000 claims description 5
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
- 229940024545 aluminum hydroxide Drugs 0.000 claims description 3
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 3
- 229960003022 amoxicillin Drugs 0.000 claims description 3
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 claims description 3
- 229960002949 fluorouracil Drugs 0.000 claims description 3
- 229960001545 hydrotalcite Drugs 0.000 claims description 3
- 229910001701 hydrotalcite Inorganic materials 0.000 claims description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 3
- 229960004768 irinotecan Drugs 0.000 claims description 3
- 229960003350 isoniazid Drugs 0.000 claims description 3
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 229960001225 rifampicin Drugs 0.000 claims description 3
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 claims description 3
- 229960002599 rifapentine Drugs 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 241000186000 Bifidobacterium Species 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 claims description 2
- 208000024330 bloating Diseases 0.000 claims description 2
- 208000010643 digestive system disease Diseases 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013373 food additive Nutrition 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- -1 neolistat Chemical compound 0.000 claims description 2
- 239000000419 plant extract Substances 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 229940100445 wheat starch Drugs 0.000 claims description 2
- 241000143437 Aciculosporium take Species 0.000 claims 1
- 241000186660 Lactobacillus Species 0.000 claims 1
- 244000199866 Lactobacillus casei Species 0.000 claims 1
- 235000013958 Lactobacillus casei Nutrition 0.000 claims 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims 1
- 235000013351 cheese Nutrition 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 229940039696 lactobacillus Drugs 0.000 claims 1
- 229940017800 lactobacillus casei Drugs 0.000 claims 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 230000006872 improvement Effects 0.000 abstract description 4
- 206010013082 Discomfort Diseases 0.000 abstract 1
- 239000002994 raw material Substances 0.000 description 47
- 241000699670 Mus sp. Species 0.000 description 16
- 239000003921 oil Substances 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 9
- 238000001514 detection method Methods 0.000 description 8
- 238000003304 gavage Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 206010009887 colitis Diseases 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 239000003925 fat Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000009629 microbiological culture Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 230000004580 weight loss Effects 0.000 description 6
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 230000003187 abdominal effect Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000013872 defecation Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102000015303 Fatty Acid Synthases Human genes 0.000 description 2
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 2
- 229940086609 Lipase inhibitor Drugs 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- JQXXHWHPUNPDRT-YOPQJBRCSA-N chembl1332716 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CCN(C)CC1 JQXXHWHPUNPDRT-YOPQJBRCSA-N 0.000 description 2
- 230000003749 cleanliness Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 229930003347 Atropine Chemical group 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Chemical group CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical group O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical group C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009920 food preservation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108010091264 gastric triacylglycerol lipase Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- IMYZQPCYWPFTAG-IQJOONFLSA-N mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 description 1
- 229960002525 mecamylamine Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000002759 monoacylglycerols Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- ALWKGYPQUAPLQC-UHFFFAOYSA-N neostigmine Chemical compound CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 ALWKGYPQUAPLQC-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Chemical group 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/23—Lactobacillus acidophilus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to the field of food, to a composition containing lactic acid bacteria and its use, and in particular to a preparation composition and use of ready-to-eat lactic acid bacteria.
- Lactic acid bacteria are a kind of probiotics, which can regulate the composition of a certain part of the host's flora, a type of active microorganisms that are beneficial to the host.
- the host mucosa and system immune function or by adjusting the balance of the intestinal flora, it promotes nutrient absorption and maintains the role of intestinal health, thereby producing single microorganisms or mixed microorganisms with clear composition that are beneficial to the health of the host.
- probiotic lactic acid bacteria can regulate the normal flora of the body’s gastrointestinal tract, maintain microecological balance, improve food digestibility and biological value, reduce serum cholesterol, control endotoxins, and inhibit the growth and reproduction of spoilage bacteria and the production of spoilage products in the intestinal tract. It produces nutrients and stimulates tissue development, thereby having an effect on the body's nutritional status, physiological functions, cell infections, drug effects, toxic reactions, immune responses, tumorigenesis, aging processes and sudden emergency responses.
- Probiotic lactic acid bacteria can not only improve the nutritional value of food, improve food flavor, increase food preservation and added value, but also its special physiological activity and nutritional function are increasingly attracting people's attention.
- Orlistat was developed by Roche, a world-renowned pharmaceutical company, in 1998. It is a new type of gastrointestinal lipase inhibitor. It is currently clinically mainly used for the treatment of patients with excess body mass and obesity. Its anti-tumor activity is also being confirmed by research. Among them, its preparation is currently the only OTC weight loss drug in the world and the only weight loss drug approved by the US FDA and my country's Food and Drug Administration. Orlistat is a long-acting and potent fatty acid synthase (FAS) inhibitor. This enzyme is not only a key enzyme for the synthesis of fatty acids, but also plays an important role in obesity, embryonic development, and tumor development.
- FAS fatty acid synthase
- Neolipase is a long-acting and potent specific gastrointestinal lipase inhibitor. It forms a covalent bond with the active serine sites of gastric lipase and pancreatic lipase in the stomach and small intestine to inactivate the enzyme. To play a therapeutic role, the inactivated enzymes cannot hydrolyze the fats in the food, mainly triglycerides, into absorbable free fatty acids and monoacylglycerols. Undigested triglycerides cannot be absorbed by the body, thereby reducing calorie intake and controlling weight. The drug does not affect the nervous system, does not affect other enzyme activities in the gastrointestinal tract, does not suppress appetite, and does not need to restrict diet. There are many such drugs, but these drugs are prone to oil leakage, abdominal pain, abdominal distension, diarrhea, constipation, etc. when taken.
- the present invention provides a composition containing lactic acid bacteria, which can be prepared into ready-to-eat lactic acid bacteria, which can be taken alone to treat diseases such as abdominal pain, bloating, and diarrhea. It can also be taken together with other drugs, such as Orly Sstat, new lisstat, etc. promote its weight loss effect and reduce the occurrence of side effects of drugs.
- the present invention is implemented as follows:
- a strain containing lactic acid bacteria comprising at least one selected from the group consisting of Lactobacillus plantarum LP45, Lactobacillus acidophilus La28, Lactobacillus paracasei YMC1069, and Bifidobacterium bifidum TMC3115.
- the Lactobacillus plantarum LP45 is 0.1-10 parts
- the Lactobacillus acidophilus La28 is 0.01-10 parts
- the Lactobacillus paracasei YMC1069 is 0.01-10 parts.
- Bifidobacterium TMC3115 is 0.01-10 parts.
- Lactobacillus plantarum LP45 this strain has been deposited in the General Microbial Culture Collection Center of the China Microbial Culture Collection Management Committee, the address is No. 1 Beichen West Road, Chaoyang District, Beijing, and the preservation date is August 26, 2013. It is: CGMCC No.8072.
- Lactobacillus acidophilus La28 this strain has been deposited in the China Common Microbial Culture Collection Management Center, and the deposit address is No. 3, No. 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, preservation date October 15, 2015 Date, the deposit number is CGMCC No. 11506.
- Bifidobacterium bifidum TMC3115 this strain has been deposited in the Common Microbial Culture Collection Center of China Microbial Culture Collection Management Committee, the address is No. 1 Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, preservation date November 2013 On 11th, the deposit number was CGMCC No. 8462.
- Lactobacillus paracasei YMC1069 this strain has been deposited in the General Microbial Culture Collection Center of China Microbial Culture Collection Management Committee, the address is No. 1 Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, preservation date October 2019 On the 14th, the deposit number was CGMCC No. 18676.
- the strains include at least two species selected from the group consisting of Lactobacillus plantarum LP45, Lactobacillus acidophilus La28, Lactobacillus paracasei YMC1069, and Bifidobacterium bifidum TMC3115.
- the strain contains at least three selected from the group consisting of Lactobacillus plantarum LP45, Lactobacillus acidophilus La28, Lactobacillus paracasei YMC1069, and Bifidobacterium bifidum TMC3115.
- the strains include Lactobacillus plantarum LP45, Lactobacillus acidophilus La28, Lactobacillus paracasei YMC1069, and Bifidobacterium bifidum TMC3115.
- composition A said composition containing the following ingredients: a) containing the strain according to any one of claims 1-5; and b) one or two of inulin and stachyose; and / Or c) Any one or two or more of powders and adhesives.
- the powder is selected from any one or a combination of two or more of starch, dextrin, flavoring, fruit powder, plant extracts, and food additives; the binder is selected from corn starch, wheat starch, and soybean starch And any of the food-acceptable adhesives.
- the powder is selected from 15-35 parts of resistant dextrin, 10-30 parts of maltodextrin, 15-40 parts of inulin, 1-10 parts of stachyose, and 10-30 parts of the binder corn starch.
- composition A containing lactic acid bacteria by weight ratio, the composition is composed of: 0.1-10 parts of Lactobacillus plantarum, 0.01-10 parts of Lactobacillus acidophilus, and 0.01-10 parts of Lactobacillus paracasei , 0.01-10 parts of Bifidobacterium bifidum, 15-35 parts of resistant dextrin, 10-30 parts of maltodextrin, 10-30 parts of corn starch, 15-40 parts of inulin, 1-10 parts of stachyose.
- the composition consists of 2.5 parts of Lactobacillus plantarum, 0.6 parts of Lactobacillus acidophilus, 0.1 part of Lactobacillus paracasei, 0.1 part of Bifidobacterium bifidum, and 28.34 parts of resistant dextrin. , 16.54 parts of maltodextrin, 19.85 parts of corn starch, 26.46 parts of inulin, 5.51 parts of stachyose.
- the said containing composition may also contain fruit powder.
- the fruit powder is selected from one or more combinations of orange fruit powder, elderberry fruit powder, cranberry fruit powder, and strawberry fruit powder;
- the composition of the composition A is: 1-4 parts of Lactobacillus plantarum LP45, 0.1-1 part of Lactobacillus acidophilus La28, and Lactobacillus paracasei YMC1069 0.01-1 part, Bifidobacterium bifidum TMC3115 0.01-1 part, resistant dextrin 20-30 parts, maltodextrin 10-20 parts, corn starch 15-25 parts, inulin 20-30 parts, stachyose 1-10 servings, 5-10 servings of fruit powder.
- the composition A is composed of 2.5 parts of Lactobacillus plantarum LP45, 0.6 parts of Lactobacillus acidophilus La28, 0.1 part of Lactobacillus paracasei YMC1069, 0.1 part of Bifidobacterium bifidum TMC3115, anti- 26.6 parts of sex dextrin, 15.5 parts of maltodextrin, 18.6 parts of corn starch, 24.8 parts of inulin, 5.2 parts of stachyose, 6.0 parts of fruit powder.
- the composition A is composed of 2.5 parts of Lactobacillus plantarum LP45, 0.6 parts of Lactobacillus acidophilus La28, 0.1 part of Lactobacillus paracasei YMC1069, 0.1 part of Bifidobacterium bifidum TMC3115, anti- 25.7 parts of sex dextrin, 15.0 parts of maltodextrin, 18.0 parts of corn starch, 24.0 parts of inulin, 5.0 parts of stachyose, and 9.0 parts of fruit powder.
- the lactic acid bacteria-containing composition A is an instant lactic acid bacteria, which can be used alone or in combination with any drug that easily causes oil leakage, abdominal pain, abdominal distension, and diarrhea, and can significantly improve oil leakage, abdominal pain, abdominal distension, diarrhea, constipation, and intestinal improvement. Microcirculation, functional dyspepsia and other effects.
- the drug is selected from diarrhea caused by sodium bicarbonate, aluminum hydroxide, hydrotalcite, amoxicillin, irinotecan, isoniazid, rifampicin, rifapentine, and fluorouracil anti-tumor drugs , As well as abdominal pain caused by neostigmine, physostigmine, enzyme quinine, mecamylamine, hexahydroxy quaternary amine, atropine, chlorpromazine, tricyclic antidepressants, and diphenhydramine.
- the composition of the present invention needs to be taken at least 2 hours apart.
- the drug when selected from orlistat and neolistat, it can be taken together with the composition of the present invention.
- composition B said composition I comprising:
- Orlistat neolistat, sodium bicarbonate, aluminum hydroxide, hydrotalcite, amoxicillin, irinotecan, isoniazid, rifampicin, rifapentine, fluorouracil anti-tumor drugs Any one is prepared into a composition for combined use or any one of them is combined for use.
- a preparation product characterized in that the preparation product is selected from any one of tablets, capsules, granules, powders, pills, oral liquids, and soft capsules.
- the preparation product contains the strain or composition A or composition B of the present invention.
- Composition A is a kind of instant lactic acid bacteria, which is a kind of food.
- composition of the present invention includes at least 10 6 to 10 12 CFU bacteria per gram of dry weight per gram of composition.
- composition according to the present invention comprising at least 108 to 10 11 CFU of bacteria / g composition per g.
- the strain of the present invention is used for preparing food products for improving gastrointestinal motility, improving intestinal motility and/or reducing intestinal permeability.
- composition A of the present invention in preparing food products for preventing and/or reducing gastrointestinal discomfort or gastrointestinal diseases.
- composition A of the present invention is used for preparing food products for improving gastrointestinal motility, improving intestinal motility and/or reducing intestinal permeability.
- composition A of the present invention in the preparation of medicines for preventing and/or reducing gastrointestinal discomfort or gastrointestinal diseases.
- composition A of the present invention in the preparation of medicines for improving gastrointestinal motility, improving intestinal motility and/or reducing intestinal permeability.
- An instant lactic acid bacteria and orlistat are used in combination to lose weight, improve oil leakage, abdominal pain, abdominal distension, diarrhea, constipation, and improve intestinal microenvironment.
- strain, composition A or composition B of the present invention can be combined with auxiliary materials to prepare tablets, capsules, granules, powders, pills, oral liquids, and soft capsules.
- Another object of the present invention is to provide a method for preparing instant lactic acid bacteria, and the process flow of the method is as follows:
- Lactobacillus plantarum Take the prescribed amount of Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus paracasei, Bifidobacterium bifidum and resistant dextrin, maltodextrin, corn starch, inulin, stachyose, and fruit powder and mix it into a uniform bacterial powder , Get it in bags;
- the instant lactic acid bacteria of the present invention can adjust the intestinal microecological balance, have a significant improvement or alleviation effect on abdominal pain, bloating, diarrhea, and constipation. It is conducive to normal laxative, safe detoxification, and improves the body’s immunity. .
- the taste is good, easy to digest, and can be made into various foods according to different people's preferences.
- the safety is high. Because the lactic acid bacteria used are edible materials, there are no side effects on the human body, so that consumers can more accept it. To Some people worry that reducing oil discharge will not achieve the weight loss effect.
- This is the composition of the present invention improving the intestinal microenvironment. By testing the weight of the subject, it is found that taking the composition of the present invention and orlistat products will not affect the weight loss effect. Some trial users also reported that their weight decreased after 1 week of trial. There are also trial users who ingested oil-rich foods within a week without gaining weight.
- Example 1 A composition containing lactic acid bacteria A , The raw materials and preparation process used are as follows:
- the composition of the raw materials is: 0.1 g of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28 0.01 g, 0.01 g Lactobacillus paracasei YMC1069, 0.01 g Bifidobacterium bifidum TMC3115, 15 g resistant dextrin, 10 g maltodextrin, 10 g corn starch, 15 g inulin, and 1 g stachyose.
- the preparation process is as follows:
- Example 2 A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
- the composition of the raw materials is: 10 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28 10 grams, Lactobacillus paracasei YMC1069 10 grams, Bifidobacterium bifidum TMC3115 10 grams, 35 grams of resistant dextrin, 30 grams of maltodextrin, 30 grams of corn starch, 40 grams of inulin, and 10 grams of stachyose.
- Example 3 A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
- the composition of the raw materials is 2.5 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28 0.6g, 0.1g of Lactobacillus paracasei YMC1069, 0.1g of Bifidobacterium bifidum TMC3115, 28.34g of resistant dextrin, 16.54g of maltodextrin, 19.85g of corn starch, 26.46g of inulin, 5.51g of stachyose.
- Example 4 A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
- the composition of the raw materials is: 1 g of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28 1 g, Lactobacillus paracasei YMC1069 1 g, Bifidobacterium bifidum TMC3115 1 g, 20 g resistant dextrin, 10 g maltodextrin, 15 g corn starch, 20 g inulin, 1 g stachyose, 5 g orange fruit powder.
- Example 5 A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
- the composition of the raw materials is: 4 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28 1 g, Lactobacillus paracasei YMC1069 1 g, Bifidobacterium bifidum TMC3115 1 gram, 30 grams of resistant dextrin, 20 grams of maltodextrin, 25 grams of corn starch, 30 grams of inulin, 10 grams of stachyose, and 10 grams of orange fruit powder.
- Example 6 A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
- the composition of the raw materials is: 1 g of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28 1 g, Lactobacillus paracasei YMC1069 1 g, Bifidobacterium bifidum TMC3115 1 gram, 20 grams of resistant dextrin, 10 grams of maltodextrin, 15 grams of corn starch, 20 grams of inulin, 1 gram of stachyose, and 5 grams of elderberry fruit powder.
- Example 7 A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
- the composition of the raw materials is: 4 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28 1 g, Lactobacillus paracasei YMC1069 1 g, Bifidobacterium bifidum TMC3115 1 gram, 30 grams of resistant dextrin, 20 grams of maltodextrin, 25 grams of corn starch, 30 grams of inulin, 10 grams of stachyose, and 10 grams of elderberry fruit powder.
- Example 8 A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
- the composition of the raw materials is 2.5 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28 0.6 g, Lactobacillus paracasei YMC1069 0.1 g, Bifidobacterium bifidum TMC3115 0.1 g, resistant dextrin 26.6 g, maltodextrin 15.5 g, corn starch 18.6 g, inulin 24.8 g, stachyose 5.2 g, vine 6.0 grams of cranberry fruit powder.
- Example 9 A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
- the composition of the raw materials is 2.5 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28 0.6 g, Lactobacillus paracasei YMC1069 0.1 g, Bifidobacterium bifidum TMC3115 0.1 g, resistant dextrin 25.7 g, maltodextrin 15.0 g, corn starch 18.0 g, inulin 24.0 g, stachyose 5.0 g, strawberry 9.0 grams of fruit powder.
- Example 10 A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
- the composition of the raw materials is 2.5 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28 0.6 g, Lactobacillus paracasei YMC1069 0.1 g, Bifidobacterium bifidum TMC3115 0.1 g, resistant dextrin 26.6 g, maltodextrin 15.5 g, corn starch 18.6 g, inulin 24.8 g, stachyose 5.2 g, vine 6.0 grams of cranberry fruit powder.
- the preparation process is the same as in Example 1.
- the above-mentioned raw materials are prepared into capsules using conventional techniques, and each capsule contains 500 mg of raw materials.
- Example 11 A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
- the composition of the raw materials is 2.5 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28 0.6 g, Lactobacillus paracasei YMC1069 0.1 g, Bifidobacterium bifidum TMC3115 0.1 g, resistant dextrin 25.7 g, maltodextrin 15.0 g, corn starch 18.0 g, inulin 24.0 g, stachyose 5.0 g, strawberry 9.0 grams of fruit powder.
- the preparation process is the same as in Example 1.
- the above-mentioned raw materials are prepared into capsules using conventional techniques, and each capsule contains 500 mg of raw materials.
- Example 12 A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
- the composition of the raw materials is 2.5 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28 0.6 g, Lactobacillus paracasei YMC1069 0.1 g, Bifidobacterium bifidum TMC3115 0.1 g, resistant dextrin 26.6 g, maltodextrin 15.5 g, corn starch 18.6 g, inulin 24.8 g, stachyose 5.2 g, vine 6.0 grams of cranberry fruit powder.
- the preparation process is the same as in Example 1.
- the above-mentioned raw materials are prepared into tablets using conventional techniques, and each tablet contains 750 mg of raw materials.
- Example 13 A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
- the composition of the raw materials is 2.5 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28 0.6 g, Lactobacillus paracasei YMC1069 0.1 g, Bifidobacterium bifidum TMC3115 0.1 g, resistant dextrin 25.7 g, maltodextrin 15.0 g, corn starch 18.0 g, inulin 24.0 g, stachyose 5.0 g, strawberry 9.0 grams of fruit powder.
- the preparation process is the same as in Example 1.
- the above-mentioned raw materials are prepared into tablets using conventional techniques, and each tablet contains 750 mg of raw materials.
- Example 14 A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
- the composition of the raw materials is 2.5 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28 0.6g, 0.1g of Lactobacillus paracasei YMC1069, 0.1g of Bifidobacterium bifidum TMC3115, 26.6g of resistant dextrin, 15.5g of maltodextrin, 18.6g of corn starch, 24.8g of inulin, 5.2g of stachyose, strawberry 6.0 grams of fruit powder.
- Example 15 A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
- the composition of the raw materials is 2.5 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28 0.6g, 0.1g of Lactobacillus paracasei YMC1069, 0.1g of Bifidobacterium bifidum TMC3115, 26.6g of resistant dextrin, 15.5g of maltodextrin, 18.6g of corn starch, 24.8g of inulin, 5.2g of stachyose, elder 6.0 grams of raspberry fruit powder.
- Example 16 A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
- the raw materials consist of 3.3 grams of Lactobacillus paracasei YMC1069, 25.7 grams of resistant dextrin, 15.0 grams of maltodextrin, 18.0 grams of corn starch, and 9.0 grams of strawberry fruit powder.
- Example 17 A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
- the composition of the raw materials is: 3.3 grams of Lactobacillus paracasei YMC1069, 25.7 grams of resistant dextrin, 15.0 grams of maltodextrin, 18.0 grams of corn starch, 24.0 grams of inulin, 5.0 grams of stachyose, strawberry 9.0 grams of fruit powder.
- Example 18 A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
- the composition of the raw materials is 2.5 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28 0.6 grams, 0.1 grams of Lactobacillus paracasei YMC1069, 0.1 grams of Bifidobacterium bifidum TMC3115.
- Comparative example 1 A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
- the raw materials consist of 26.6 grams of resistant dextrin, 15.5 grams of maltodextrin, 18.6 grams of corn starch, 24.8 grams of inulin, 5.2 grams of stachyose, and 6.0 grams of elderberry fruit powder.
- composition of the present invention improves and relieves oil leakage
- mice Kunming pure-bred mice are provided by Lunan Pharmaceutical Group Co., Ltd.
- the batch number of the laboratory animal certificate is: SYXK ( ⁇ )20180008, half male and half, 3-4 weeks old, weighing 16-20g.
- composition/drug involved in the experiment the composition of Example 1, Example 2, Example 3, Example 8, Example 9, Example 16, Example 17, and Example 18, orlistat capsule ( Shandong New Times Pharmaceutical Co., Ltd., batch number: 085190604).
- mice After buying back, raise the mice for one week to adapt to the environment.
- Hindquarters cleanliness reflects the oil leakage of mice from the side. Generally speaking, mice are clean after 5 points, relatively clean 3 points, generally 1 point, 0 points difference.
- Colitis is clinically manifested as pain, abdominal distension, diarrhea and other phenomena. Therefore, this experiment verified the effects of various compositions of the embodiments of the present invention by constructing a mouse colitis animal model experiment, and conducted related pharmacodynamic analysis. details as follows:
- mice Kunming pure-bred mice are provided by Lunan Pharmaceutical Group Co., Ltd.
- the batch number of the laboratory animal certificate is: SYXK ( ⁇ ) 2018 0008, half male and half male, 3-4 weeks old, weighing 16-20g.
- composition/drug involved in the experiment Example 1, Example 2, Example 3, Example 8, Example 9, Example 16, Example 17, Example 18 Products, Orlistat Capsule (Shandong New Times Pharmaceutical Co., Ltd., batch number: 085190604), Changyanning tablets (Jiangxi Tianshi Kang Yiyang Pharmaceutical Co., Ltd.).
- mice After applying oxazolone, the local skin of the mice appeared red and swollen. After 5 days, the mice were given a small dose of oxazolone again by enema, and the mice quickly developed intestinal inflammation, and the mouse colitis model was established.
- mice were reared for a week to adapt to the environment after the purchase, and the mice were randomly divided into groups of 10 each, a total of 10 groups, divided into group A, group B, group C, group D, group E, group F, group G, above Kunming Mice were injected with Sumianxin anesthesia by intramuscular injection, the abdominal skin was shaved (1.5cm ⁇ 1.5cm), and 0.2ml of 3% oxazolone (dissolved in 100% ethanol) was applied to the skin after 1 day. Repeat the application once after 5 days.
- a 2mm diameter silicone tube was inserted into the mouse intestine from the anus to a depth of about 4cm, and 0.15ml of oxazolone (dissolved in 50% ethanol) was injected. After 72 hours, the mouse modeling was completed. In addition, the abdominal skin of 10 mice was shaved (1.5cm ⁇ 1.5cm), and normal saline was applied. After 5 days, a silicone tube with a diameter of 2mm was inserted into the mouse’s intestine from the anus to a depth of about 4cm, and 0.15ml of normal saline was injected.
- Detection indicators diarrhea and pain.
- the most obvious manifestation of colitis is diarrhea, that is, the number of stools, which is the most intuitive result of colitis.
- the experiment of the present invention counts the number of stools in mice within 24 hours; another sign of colitis is pain, the inventor By observing the number of twists of the mouse body within 8 hours, the mouse twists half a circle or more than half a circle once. Body weight change (weigh weight after 5 days-weight before experiment), the test results of each group are shown in Table 2.
- Table 2 show the weight of the mice, the number of stools and the number of body torsions.
- the comparison between group b and group b shows that the model was successfully modeled.
- group A, group B, group C, group D, group E, group F, group G, and group H can all play a very obvious role in treatment, which is mainly manifested as a significant increase in weight, reduction of stool frequency and pain frequency, but C
- the overall effect of group, D group, and E group is better than that of group A, group B, group E, group F, and group H, which may be the effect difference caused by the change of raw material weight.
- Example 3 Example 8, Example 9, Example 14, Example 15, Example 16, Example 17, Example 18, Comparative Example 1, Orlistat Capsule (Shandong New Times Medicine Industry Co., Ltd., specification: 100mg, production batch number: 085190604-085190607)
- BMI Body mass index
- Oil leakage The degree of oil leakage reduction when the air is in the air: 10 points for very satisfactory, 7 points for satisfaction, 3 points for general, 1 point for difference.
- Smell the degree of fragrance of the composition of the present invention: very satisfactory 10 points, satisfactory 7 points, general 3 points, 1 point difference.
- Exhaust reduction degree very satisfactory 10 points, satisfactory 7 points, general 3 points, 1 point difference.
- Abdominal pain, abdominal ringing, and abdominal distension the degree of abdominal pain, abdominal ringing, and abdominal distension is very satisfactory 10 points, satisfactory 7 points, general 3 points, 1 point difference.
- Results Summarize the final scores and use spss19.0 for statistical analysis.
- Sensory measurement the color, smell, state of the product, and whether there are foreign objects visible to the naked eye.
- the moisture detection method is in accordance with the first method of GB5009.3-2016, and the lead detection method is in accordance with the first method of GB5009.12-2017.
- Microbial indicators detection of the total number of lactic acid bacteria, molds and other microorganisms.
- the determination of the total number of lactic acid bacteria uses the GB4789.35-2016 method to detect, the Staphylococcus aureus GB4789.10-2016 the second method, the Salmonella GB4789.4-2016, and the mold GB4789.15-2016 first Method detection, E. coli GB4789.3-2016 second method detection.
- the strain content of each example is more than 20 billion, which meets food-related requirements.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
A composition containing lactic acid bacteria and use thereof. The composition contains Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus paracasei, Bifidobacterium bifidum, resistant dextrin, maltodextrin, corn starch, inulin, stachyose and other components. The composition can regulate the intestinal microecological balance, and have a significant improvement effect on abdominal pain, abdominal distension, diarrhea, and constipation, and can alleviate discomforts caused by taking Orlistat and other drugs.
Description
本发明涉及食品领域，涉及含乳酸菌的组合物及其用途，尤其涉及一种即食型乳酸菌制备组成以及用途。The present invention relates to the field of food, to a composition containing lactic acid bacteria and its use, and in particular to a preparation composition and use of ready-to-eat lactic acid bacteria.
乳酸菌是益生菌的一种，可调节宿主某一部位菌群组成的一类对宿主有益的活性微生物。通过调节宿主黏膜与系统免疫功能或通过调节肠道内菌群平衡，促进营养吸收保持肠道健康的作用，从而产生有利于宿主健康作用的单微生物或组成明确的混合微生物。Lactic acid bacteria are a kind of probiotics, which can regulate the composition of a certain part of the host's flora, a type of active microorganisms that are beneficial to the host. By adjusting the host mucosa and system immune function or by adjusting the balance of the intestinal flora, it promotes nutrient absorption and maintains the role of intestinal health, thereby producing single microorganisms or mixed microorganisms with clear composition that are beneficial to the health of the host.
作为一种存在于人类体内的益生菌--乳酸菌（lactic acid
bacteria，LAB）是一类能利用可发酵碳水化合物产生大量乳酸的细菌的通称，能够帮助消化，有助人体肠脏的健康。大量研究表明，益生乳酸菌能够调节机体胃肠道正常菌群、保持微生态平衡，提高食物消化率和生物价，降低血清胆固醇，控制内毒素，抑制肠道内腐败菌生长繁殖和腐败产物的产生，制造营养物质，刺激组织发育，从而对机体的营养状态、生理功能、细胞感染、药物效应、毒性反应、免疫反应、肿瘤发生、衰老过程和突然的应急反应等产生作用。益生乳酸菌不仅可以提高食品的营养价值，改善食品风味，提高食品保藏性和附加值，而且其特殊的生理活性和营养功能正日益引起人们的重视。As a kind of probiotics that exist in the human body-lactic acid bacteria
Bacteria, LAB) is a general term for bacteria that can use fermentable carbohydrates to produce large amounts of lactic acid, which can help digestion and contribute to the health of the human intestines. A large number of studies have shown that probiotic lactic acid bacteria can regulate the normal flora of the body’s gastrointestinal tract, maintain microecological balance, improve food digestibility and biological value, reduce serum cholesterol, control endotoxins, and inhibit the growth and reproduction of spoilage bacteria and the production of spoilage products in the intestinal tract. It produces nutrients and stimulates tissue development, thereby having an effect on the body's nutritional status, physiological functions, cell infections, drug effects, toxic reactions, immune responses, tumorigenesis, aging processes and sudden emergency responses. Probiotic lactic acid bacteria can not only improve the nutritional value of food, improve food flavor, increase food preservation and added value, but also its special physiological activity and nutritional function are increasingly attracting people's attention.
奥利司他由全球著名制药企业罗氏公司于1998年研发，是一种新型胃肠脂肪酶抑制剂，目前临床主要用于体质量超标及肥胖症患者的治疗，其抗肿瘤活性亦在研究确认当中，其制剂是目前全球唯一的OTC减肥药，也是唯一被美国FDA和我国食品药品监督管理局批准的减肥药。奥利司他是长效和强效的脂肪酸合成酶（FAS）抑制剂，该酶不仅是合成脂肪酸的关键酶，也在肥胖，胚胎发育，和肿瘤发展中扮演重要角色。新利司他为一种长效和强效的特异性胃肠道脂肪酶抑制剂，通过与胃和小肠腔内胃脂肪酶和胰脂肪酶的活性丝氨酸部位形成共价键使酶失活而发挥治疗作用，失活的酶不能将食物中的脂肪主要是甘油三酯水解为可吸收的游离脂肪酸和单酰基甘油。未消化的甘油三酯不能被身体吸收，从而减少热量摄入，控制体重，该药不作用与神经系统，不影响胃肠道的其他酶活性，不抑制食欲，无需限制饮食。诸如此类的药物很多，但是这些药物在服用时易产生漏油、腹痛、腹胀、腹泻、便秘等现象。Orlistat was developed by Roche, a world-renowned pharmaceutical company, in 1998. It is a new type of gastrointestinal lipase inhibitor. It is currently clinically mainly used for the treatment of patients with excess body mass and obesity. Its anti-tumor activity is also being confirmed by research. Among them, its preparation is currently the only OTC weight loss drug in the world and the only weight loss drug approved by the US FDA and my country's Food and Drug Administration. Orlistat is a long-acting and potent fatty acid synthase (FAS) inhibitor. This enzyme is not only a key enzyme for the synthesis of fatty acids, but also plays an important role in obesity, embryonic development, and tumor development. Neolipase is a long-acting and potent specific gastrointestinal lipase inhibitor. It forms a covalent bond with the active serine sites of gastric lipase and pancreatic lipase in the stomach and small intestine to inactivate the enzyme. To play a therapeutic role, the inactivated enzymes cannot hydrolyze the fats in the food, mainly triglycerides, into absorbable free fatty acids and monoacylglycerols. Undigested triglycerides cannot be absorbed by the body, thereby reducing calorie intake and controlling weight. The drug does not affect the nervous system, does not affect other enzyme activities in the gastrointestinal tract, does not suppress appetite, and does not need to restrict diet. There are many such drugs, but these drugs are prone to oil leakage, abdominal pain, abdominal distension, diarrhea, constipation, etc. when taken.
鉴于此，本发明提供了一种含有乳酸菌的组合物，将该组合物可以制备成即食型乳酸菌，单独服用可用来治疗腹痛、腹胀、腹泻等疾病，还可以与其他药物一起服用，例如奥利司他、新利司他等促进其减肥效果，减少药物的副作用发生。In view of this, the present invention provides a composition containing lactic acid bacteria, which can be prepared into ready-to-eat lactic acid bacteria, which can be taken alone to treat diseases such as abdominal pain, bloating, and diarrhea. It can also be taken together with other drugs, such as Orly Sstat, new lisstat, etc. promote its weight loss effect and reduce the occurrence of side effects of drugs.
具体而言，本发明是这样实现的：Specifically, the present invention is implemented as follows:
一种含乳酸菌的菌株，所述菌株至少包含一种选自植物乳杆菌LP45、嗜酸乳杆菌La28、副干酪乳杆菌YMC1069、两歧双歧杆菌TMC3115。按重量比计，所述的植物乳杆菌LP45为 0.1-10份，所述的嗜酸乳杆菌La28为0.01-10份，所述的副干酪乳杆菌YMC1069为0.01-10份，所述的两歧双歧杆菌TMC3115为0.01-10份。A strain containing lactic acid bacteria, said strain comprising at least one selected from the group consisting of Lactobacillus plantarum LP45, Lactobacillus acidophilus La28, Lactobacillus paracasei YMC1069, and Bifidobacterium bifidum TMC3115. In terms of weight ratio, the Lactobacillus plantarum LP45 is 0.1-10 parts, the Lactobacillus acidophilus La28 is 0.01-10 parts, and the Lactobacillus paracasei YMC1069 is 0.01-10 parts. Bifidobacterium TMC3115 is 0.01-10 parts.
其中，植物乳杆菌LP45，该菌株在中国微生物菌种保藏管理委员会普通微生物菌种保藏中心进行了保藏，地址为北京市朝阳区北辰西路1号院，保藏日期2013年8月26日保藏号为：CGMCC No .8072。Among them, Lactobacillus plantarum LP45, this strain has been deposited in the General Microbial Culture Collection Center of the China Microbial Culture Collection Management Committee, the address is No. 1 Beichen West Road, Chaoyang District, Beijing, and the preservation date is August 26, 2013. It is: CGMCC No.8072.
嗜酸乳杆菌La28，该菌株在中国普通微生物菌种保藏管理中心进行了保藏，保藏地址为北京市朝阳区北辰西路1号院3号，中国科学院微生物研究所，保藏日期2015年10月15日，保藏号为CGMCC No .11506。Lactobacillus acidophilus La28, this strain has been deposited in the China Common Microbial Culture Collection Management Center, and the deposit address is No. 3, No. 1, Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, preservation date October 15, 2015 Date, the deposit number is CGMCC No. 11506.
两歧双歧杆菌TMC3115，该菌株在中国微生物菌种保藏管理委员会普通微生物菌种保藏中心进行了保藏，地址为北京市朝阳区北辰西路1号院，中科院微生物研究所，保藏日期2013 年11 月11 日，保藏号为CGMCC No .8462。Bifidobacterium bifidum TMC3115, this strain has been deposited in the Common Microbial Culture Collection Center of China Microbial Culture Collection Management Committee, the address is No. 1 Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, preservation date November 2013 On 11th, the deposit number was CGMCC No. 8462.
副干酪乳杆菌YMC1069，该菌株在中国微生物菌种保藏管理委员会普通微生物菌种保藏中心进行了保藏，地址为北京市朝阳区北辰西路1号院，中科院微生物研究所，保藏日期2019 年10 月14 日，保藏号为CGMCC No .18676。Lactobacillus paracasei YMC1069, this strain has been deposited in the General Microbial Culture Collection Center of China Microbial Culture Collection Management Committee, the address is No. 1 Beichen West Road, Chaoyang District, Beijing, Institute of Microbiology, Chinese Academy of Sciences, preservation date October 2019 On the 14th, the deposit number was CGMCC No. 18676.
所述菌株至少包含二种选自植物乳杆菌LP45、嗜酸乳杆菌La28、副干酪乳杆菌YMC1069、两歧双歧杆菌TMC3115。The strains include at least two species selected from the group consisting of Lactobacillus plantarum LP45, Lactobacillus acidophilus La28, Lactobacillus paracasei YMC1069, and Bifidobacterium bifidum TMC3115.
所述菌株至少包含三种选自植物乳杆菌LP45、嗜酸乳杆菌La28、副干酪乳杆菌YMC1069、两歧双歧杆菌TMC3115。The strain contains at least three selected from the group consisting of Lactobacillus plantarum LP45, Lactobacillus acidophilus La28, Lactobacillus paracasei YMC1069, and Bifidobacterium bifidum TMC3115.
所述菌株包含植物乳杆菌LP45、嗜酸乳杆菌La28、副干酪乳杆菌YMC1069、两歧双歧杆菌TMC3115。The strains include Lactobacillus plantarum LP45, Lactobacillus acidophilus La28, Lactobacillus paracasei YMC1069, and Bifidobacterium bifidum TMC3115.
一种组合物A，所述的组合物含有以下成分：a）含有如权利要求1-5任一项所述的菌株；和b）菊粉、水苏糖中的一种或两种；和/或c）粉剂、粘合剂中的任意一种或者二种以上。A composition A, said composition containing the following ingredients: a) containing the strain according to any one of claims 1-5; and b) one or two of inulin and stachyose; and / Or c) Any one or two or more of powders and adhesives.
所述粉剂选自淀粉、糊精、调味剂、水果粉、植物提取物以及食品上的添加剂中的任意一种或两种以上组合；所述粘合剂选自玉米淀粉、小麦淀粉、大豆淀粉以及食品上可接受的粘合剂的任意一种。The powder is selected from any one or a combination of two or more of starch, dextrin, flavoring, fruit powder, plant extracts, and food additives; the binder is selected from corn starch, wheat starch, and soybean starch And any of the food-acceptable adhesives.
所述粉剂选自抗性糊精15-35份，麦芽糊精10-30份，菊粉15-40份，水苏糖1-10份，所述的粘合剂玉米淀粉10-30份。The powder is selected from 15-35 parts of resistant dextrin, 10-30 parts of maltodextrin, 15-40 parts of inulin, 1-10 parts of stachyose, and 10-30 parts of the binder corn starch.
进一步地，一种含有乳酸菌的组合物A，按重量比计，所述组合物的组成为：植物乳杆菌0.1-10份，嗜酸乳杆菌0.01-10份，副干酪乳杆菌0.01-10份，两歧双歧杆菌0.01-10份，抗性糊精15-35份，麦芽糊精10-30份，玉米淀粉10-30份，菊粉15-40份，水苏糖1-10份。Further, a composition A containing lactic acid bacteria, by weight ratio, the composition is composed of: 0.1-10 parts of Lactobacillus plantarum, 0.01-10 parts of Lactobacillus acidophilus, and 0.01-10 parts of Lactobacillus paracasei , 0.01-10 parts of Bifidobacterium bifidum, 15-35 parts of resistant dextrin, 10-30 parts of maltodextrin, 10-30 parts of corn starch, 15-40 parts of inulin, 1-10 parts of stachyose.
优选地，按重量比计，所述组合物的组成为：植物乳杆菌2.5份，嗜酸乳杆菌0.6份，副干酪乳杆菌0.1份，两歧双歧杆菌0.1份，抗性糊精28.34份，麦芽糊精16.54份，玉米淀粉19.85份，菊粉26.46份，水苏糖5.51份。Preferably, by weight ratio, the composition consists of 2.5 parts of Lactobacillus plantarum, 0.6 parts of Lactobacillus acidophilus, 0.1 part of Lactobacillus paracasei, 0.1 part of Bifidobacterium bifidum, and 28.34 parts of resistant dextrin. , 16.54 parts of maltodextrin, 19.85 parts of corn starch, 26.46 parts of inulin, 5.51 parts of stachyose.
所述含有组合物的还可以含有水果粉。所述的水果粉选自柳橙水果粉、接骨木莓水果粉、蔓越莓水果粉、草莓水果粉中的一种或两种以上的组合物；The said containing composition may also contain fruit powder. The fruit powder is selected from one or more combinations of orange fruit powder, elderberry fruit powder, cranberry fruit powder, and strawberry fruit powder;
优选地，按重量比计，所述组合物A的组成为：植物乳杆菌LP45 1-4份，嗜酸乳杆菌La28 0.1-1份，副干酪乳杆菌YMC1069
0.01-1份，两歧双歧杆菌TMC3115 0.01-1份，抗性糊精20-30份，麦芽糊精10-20份，玉米淀粉15-25份，菊粉20-30份，水苏糖1-10份，水果粉5-10份。Preferably, by weight ratio, the composition of the composition A is: 1-4 parts of Lactobacillus plantarum LP45, 0.1-1 part of Lactobacillus acidophilus La28, and Lactobacillus paracasei YMC1069
0.01-1 part, Bifidobacterium bifidum TMC3115 0.01-1 part, resistant dextrin 20-30 parts, maltodextrin 10-20 parts, corn starch 15-25 parts, inulin 20-30 parts, stachyose 1-10 servings, 5-10 servings of fruit powder.
优选地，按重量比计，所述组合物A的组成为：植物乳杆菌LP45 2.5份，嗜酸乳杆菌La28 0.6份，副干酪乳杆菌YMC1069 0.1份，两歧双歧杆菌TMC3115 0.1份，抗性糊精26.6份，麦芽糊精15.5份，玉米淀粉18.6份，菊粉24.8份，水苏糖5.2份，水果粉6.0份。Preferably, by weight ratio, the composition A is composed of 2.5 parts of Lactobacillus plantarum LP45, 0.6 parts of Lactobacillus acidophilus La28, 0.1 part of Lactobacillus paracasei YMC1069, 0.1 part of Bifidobacterium bifidum TMC3115, anti- 26.6 parts of sex dextrin, 15.5 parts of maltodextrin, 18.6 parts of corn starch, 24.8 parts of inulin, 5.2 parts of stachyose, 6.0 parts of fruit powder.
优选地，按重量比计，所述组合物A的组成为：植物乳杆菌LP45 2.5份，嗜酸乳杆菌La28 0.6份，副干酪乳杆菌YMC1069 0.1份，两歧双歧杆菌TMC3115 0.1份，抗性糊精25.7份，麦芽糊精15.0份，玉米淀粉18.0份，菊粉24.0份，水苏糖5.0份，水果粉9.0份。Preferably, by weight ratio, the composition A is composed of 2.5 parts of Lactobacillus plantarum LP45, 0.6 parts of Lactobacillus acidophilus La28, 0.1 part of Lactobacillus paracasei YMC1069, 0.1 part of Bifidobacterium bifidum TMC3115, anti- 25.7 parts of sex dextrin, 15.0 parts of maltodextrin, 18.0 parts of corn starch, 24.0 parts of inulin, 5.0 parts of stachyose, and 9.0 parts of fruit powder.
所述含乳酸菌的组合物A为即食型乳酸菌，可单独或者与容易导致漏油、腹痛、腹胀、腹泻任一种药物联用，具有显著改善漏油、腹痛、腹胀、腹泻、便秘、改善肠道微循环、功能性消化不良等功效。The lactic acid bacteria-containing composition A is an instant lactic acid bacteria, which can be used alone or in combination with any drug that easily causes oil leakage, abdominal pain, abdominal distension, and diarrhea, and can significantly improve oil leakage, abdominal pain, abdominal distension, diarrhea, constipation, and intestinal improvement. Microcirculation, functional dyspepsia and other effects.
进一步地，所述的药物选自碳酸氢钠、氢氧化铝、铝碳酸镁、阿莫西林、伊立替康、异烟肼、利福平、利福喷汀、氟尿嘧啶类抗肿瘤药物引起的腹泻，以及新斯的明、毒扁豆碱、酶抑宁、美加明、六羟季胺、阿托品、氯丙嗪、三环抗抑郁剂、苯海拉明引起的腹痛。服用以上药物时，在服用本发明组合物需要至少间隔2小时进行服用。Further, the drug is selected from diarrhea caused by sodium bicarbonate, aluminum hydroxide, hydrotalcite, amoxicillin, irinotecan, isoniazid, rifampicin, rifapentine, and fluorouracil anti-tumor drugs , As well as abdominal pain caused by neostigmine, physostigmine, enzyme quinine, mecamylamine, hexahydroxy quaternary amine, atropine, chlorpromazine, tricyclic antidepressants, and diphenhydramine. When taking the above drugs, the composition of the present invention needs to be taken at least 2 hours apart.
更进一步地，所述的药物选自奥利司他、新利司他的一种时，可与本发明的组合物一起服用。Furthermore, when the drug is selected from orlistat and neolistat, it can be taken together with the composition of the present invention.
一种组合物B，所述的组合物I包含：A composition B, said composition I comprising:
a）即食型乳酸菌和a) Ready-to-eat lactic acid bacteria and
b）奥利司他、新利司他、碳酸氢钠、氢氧化铝、铝碳酸镁、阿莫西林、伊立替康、异烟肼、利福平、利福喷汀、氟尿嘧啶类抗肿瘤药物任意一种制备成组合物联合使用或其任意一种联合使用。b) Orlistat, neolistat, sodium bicarbonate, aluminum hydroxide, hydrotalcite, amoxicillin, irinotecan, isoniazid, rifampicin, rifapentine, fluorouracil anti-tumor drugs Any one is prepared into a composition for combined use or any one of them is combined for use.
一种制剂产品，其特征在于，所述的制剂产品选自片剂、胶囊剂、颗粒剂、粉剂、丸剂、口服液、软胶囊中的任意一种。所述的制剂产品含有本发明所述的菌株或组合物A或组合物B。A preparation product, characterized in that the preparation product is selected from any one of tablets, capsules, granules, powders, pills, oral liquids, and soft capsules. The preparation product contains the strain or composition A or composition B of the present invention.
组合物A是一种即食型乳酸菌，是一种食品。Composition A is a kind of instant lactic acid bacteria, which is a kind of food.
本发明所述的组合物，其每g干重包括至少10
6至10
12CFU细菌/g组合物。
The composition of the present invention includes at least 10 6 to 10 12 CFU bacteria per gram of dry weight per gram of composition.
本发明所述的组合物，其每g干重包括至少10
8至10
11CFU细菌/g组合物。
The composition according to the present invention, the dry weight thereof comprising at least 108 to 10 11 CFU of bacteria / g composition per g.
本发明所述的菌株在制备用于预防和/或减轻胃肠不适或胃肠疾病的食品中的用途。Use of the strain of the present invention in preparing food for preventing and/or reducing gastrointestinal discomfort or gastrointestinal disease.
本发明所述的菌株在制备用于改善胃肠运动性、改善肠道蠕动和/或降低肠道渗透性的食品产品中的用途。The strain of the present invention is used for preparing food products for improving gastrointestinal motility, improving intestinal motility and/or reducing intestinal permeability.
本发明所述的组合物A在制备用于预防和/或减轻胃肠不适或胃肠疾病的食品产品中的用途。Use of the composition A of the present invention in preparing food products for preventing and/or reducing gastrointestinal discomfort or gastrointestinal diseases.
本发明所述的组合物A在制备用于改善胃肠运动性、改善肠道蠕动和/或降低肠道渗透性的食品产品中的用途。The composition A of the present invention is used for preparing food products for improving gastrointestinal motility, improving intestinal motility and/or reducing intestinal permeability.
本发明所述的组合物A在制备用于预防和/或减轻胃肠不适或胃肠疾病的药品中的用途。The use of the composition A of the present invention in the preparation of medicines for preventing and/or reducing gastrointestinal discomfort or gastrointestinal diseases.
本发明所述的组合物A在制备用于改善胃肠运动性、改善肠道蠕动和/或降低肠道渗透性的药品中的用途。The use of the composition A of the present invention in the preparation of medicines for improving gastrointestinal motility, improving intestinal motility and/or reducing intestinal permeability.
一种即食型乳酸菌与奥利司他联用在减肥、改善漏油、腹痛、腹胀、腹泻、便秘、改善肠道微环境中的应用。An instant lactic acid bacteria and orlistat are used in combination to lose weight, improve oil leakage, abdominal pain, abdominal distension, diarrhea, constipation, and improve intestinal microenvironment.
通过人体试验发现，在服用本发明组合物A之后，再服用奥利司他、新利司他就不会出现在矢气时带出油性物质，从而避免尴尬。Through human experiments, it is found that after taking the composition A of the present invention, taking orlistat and neolistat will not bring out oily substances in the qi, thereby avoiding embarrassment.
另，本发明所述的菌株、组合物A或组合物B均可以与辅料结合制备成片剂、胶囊剂、颗粒剂、粉剂、丸剂、口服液、软胶囊中。In addition, the strain, composition A or composition B of the present invention can be combined with auxiliary materials to prepare tablets, capsules, granules, powders, pills, oral liquids, and soft capsules.
本发明的另一目的在于提供一种即食型乳酸菌的制备方法，该方法工艺流程为：Another object of the present invention is to provide a method for preparing instant lactic acid bacteria, and the process flow of the method is as follows:
取处方量的植物乳杆菌、嗜酸乳杆菌、副干酪乳杆菌、两歧双歧杆菌与抗性糊精、麦芽糊精、玉米淀粉、菊粉、水苏糖、水果粉混合均匀成菌粉，装袋即得；Take the prescribed amount of Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus paracasei, Bifidobacterium bifidum and resistant dextrin, maltodextrin, corn starch, inulin, stachyose, and fruit powder and mix it into a uniform bacterial powder , Get it in bags;
更具体为：More specifically:
（1）取处方量的玉米淀粉制备成粘合剂，取处方量的植物乳杆菌、嗜酸乳杆菌、副干酪乳杆菌、两歧双歧杆菌混合均匀成菌粉，备用；(1) Take prescription amount of corn starch to prepare adhesive, take prescription amount of Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus paracasei, and Bifidobacterium bifidum and mix them to form a bacterial powder for use;
（2）取处方量的抗性糊精、麦芽糊精、菊粉、水苏糖、水果粉搅拌混匀制备成混合物；喷粘合剂造粒，灭菌，过筛，再与菌粉混合，即得。(2) Take the prescribed amount of resistant dextrin, maltodextrin, inulin, stachyose, and fruit powder to prepare a mixture; spray the adhesive to granulate, sterilize, sieving, and then mix with the bacterial powder , That is.
在动物模试验中，本发明的即食型乳酸菌，具有调节肠道微生态平衡，对腹痛、腹胀、腹泻、便秘具有显著的改善或缓解效果，有利于正常通便，安全排毒，提高机体免疫力。In the animal model test, the instant lactic acid bacteria of the present invention can adjust the intestinal microecological balance, have a significant improvement or alleviation effect on abdominal pain, bloating, diarrhea, and constipation. It is conducive to normal laxative, safe detoxification, and improves the body’s immunity. .
在人体的口感度测试上，口味佳、易消化，可以根据各人不同喜欢做成各种食品。安全性高，由于所采用的乳酸菌为食用性的材料，对人体没有副作用，让消费者能更够接受。
有些人担心减少了排油达不到减肥效果，这是本发明组合物改善肠道微环境，通过检测受试者的体重发现，服用本发明组合物和奥利司他产品不会影响减肥效果，一些试服者也反馈试服1周后体重有下降。也有试服者在一周内摄入含油高的食物也没有增加体重。In the taste test of the human body, the taste is good, easy to digest, and can be made into various foods according to different people's preferences. The safety is high. Because the lactic acid bacteria used are edible materials, there are no side effects on the human body, so that consumers can more accept it. To
Some people worry that reducing oil discharge will not achieve the weight loss effect. This is the composition of the present invention improving the intestinal microenvironment. By testing the weight of the subject, it is found that taking the composition of the present invention and orlistat products will not affect the weight loss effect. Some trial users also reported that their weight decreased after 1 week of trial. There are also trial users who ingested oil-rich foods within a week without gaining weight.
以下通过具体实施例进一步描述本发明，但本发明并不仅仅限于以下实施例，任何形式的等同替换对本领域普通技术人员来说都是显而易见且包含在本发明之中的。The present invention is further described by specific examples below, but the present invention is not limited to the following examples, and any form of equivalent replacement is obvious to those of ordinary skill in the art and is included in the present invention.
实施例Example
11
：一种含有乳酸菌的组合物：A composition containing lactic acid bacteria
AA
，所用的原料与制备工艺如下：, The raw materials and preparation process used are as follows:
按重量比计，所述原料的组成为：植物乳杆菌LP45 0.1克，嗜酸乳杆菌La28
0.01克，副干酪乳杆菌YMC1069 0.01克，两歧双歧杆菌TMC3115 0.01克，抗性糊精15克，麦芽糊精10克，玉米淀粉10克，菊粉15克，水苏糖1克。In terms of weight ratio, the composition of the raw materials is: 0.1 g of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28
0.01 g, 0.01 g Lactobacillus paracasei YMC1069, 0.01 g Bifidobacterium bifidum TMC3115, 15 g resistant dextrin, 10 g maltodextrin, 10 g corn starch, 15 g inulin, and 1 g stachyose.
制备工艺如下：The preparation process is as follows:
（1）取处方量的玉米淀粉制备成粘合剂，取处方量的植物乳杆菌、嗜酸乳杆菌、副干酪乳杆菌混合均匀成菌粉，备用；(1) Take prescription amount of corn starch to prepare adhesive, take prescription amount of Lactobacillus plantarum, Lactobacillus acidophilus, and Lactobacillus paracasei and mix them to form a bacterial powder for use;
（2）取处方量的抗性糊精、麦芽糊精、玉米淀粉、菊粉、水苏糖、水果粉搅拌混匀制备成混合物；喷粘合剂造粒，灭菌，过筛，再与菌粉混合，即得。(2) Take the prescribed amount of resistant dextrin, maltodextrin, corn starch, inulin, stachyose, and fruit powder, stir and mix to prepare a mixture; spray the adhesive to granulate, sterilize, sieving, and then mix with Mix the bacteria powder and get it.
实施例Example
22
：一种含有乳酸菌的组合物，所用的原料与制备工艺如下：: A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
按重量比计，所述原料的组成为：植物乳杆菌LP45 10克，嗜酸乳杆菌La28
10克，副干酪乳杆菌YMC1069 10克，两歧双歧杆菌TMC3115
10克，抗性糊精35克，麦芽糊精30克，玉米淀粉30克，菊粉40克，水苏糖10克。In terms of weight ratio, the composition of the raw materials is: 10 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28
10 grams, Lactobacillus paracasei YMC1069 10 grams, Bifidobacterium bifidum TMC3115
10 grams, 35 grams of resistant dextrin, 30 grams of maltodextrin, 30 grams of corn starch, 40 grams of inulin, and 10 grams of stachyose.
制备工艺同实施例1。The preparation process is the same as in Example 1.
实施例Example
33
：一种含有乳酸菌的组合物，所用的原料与制备工艺如下：: A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
按重量比计，所述原料的组成为：植物乳杆菌LP45 2.5克，嗜酸乳杆菌La28
0.6克，副干酪乳杆菌YMC1069 0.1克，两歧双歧杆菌TMC3115 0.1克，抗性糊精28.34克，麦芽糊精16.54克，玉米淀粉19.85克，菊粉26.46克，水苏糖5.51克。In terms of weight ratio, the composition of the raw materials is 2.5 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28
0.6g, 0.1g of Lactobacillus paracasei YMC1069, 0.1g of Bifidobacterium bifidum TMC3115, 28.34g of resistant dextrin, 16.54g of maltodextrin, 19.85g of corn starch, 26.46g of inulin, 5.51g of stachyose.
制备工艺同实施例1。The preparation process is the same as in Example 1.
实施例Example
44
：一种含有乳酸菌的组合物，所用的原料与制备工艺如下：: A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
按重量比计，所述原料的组成为：植物乳杆菌LP45 1克，嗜酸乳杆菌La28
1克，副干酪乳杆菌YMC1069 1克，两歧双歧杆菌TMC3115
1克，抗性糊精20克，麦芽糊精10克，玉米淀粉15克，菊粉20克，水苏糖1克，柳橙水果粉5克。In terms of weight ratio, the composition of the raw materials is: 1 g of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28
1 g, Lactobacillus paracasei YMC1069 1 g, Bifidobacterium bifidum TMC3115
1 g, 20 g resistant dextrin, 10 g maltodextrin, 15 g corn starch, 20 g inulin, 1 g stachyose, 5 g orange fruit powder.
制备工艺同实施例1。The preparation process is the same as in Example 1.
实施例Example
55
：一种含有乳酸菌的组合物，所用的原料与制备工艺如下：: A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
按重量比计，所述原料的组成为：植物乳杆菌LP45 4克，嗜酸乳杆菌La28
1克，副干酪乳杆菌YMC1069 1克，两歧双歧杆菌TMC3115
1克，抗性糊精30克，麦芽糊精20克，玉米淀粉25克，菊粉30克，水苏糖10克，柳橙水果粉10克。In terms of weight ratio, the composition of the raw materials is: 4 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28
1 g, Lactobacillus paracasei YMC1069 1 g, Bifidobacterium bifidum TMC3115
1 gram, 30 grams of resistant dextrin, 20 grams of maltodextrin, 25 grams of corn starch, 30 grams of inulin, 10 grams of stachyose, and 10 grams of orange fruit powder.
制备工艺同实施例1。The preparation process is the same as in Example 1.
实施例Example
66
：一种含有乳酸菌的组合物，所用的原料与制备工艺如下：: A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
按重量比计，所述原料的组成为：植物乳杆菌LP45 1克，嗜酸乳杆菌La28
1克，副干酪乳杆菌YMC1069 1克，两歧双歧杆菌TMC3115
1克，抗性糊精20克，麦芽糊精10克，玉米淀粉15克，菊粉20克，水苏糖1克，接骨木莓水果粉5克。In terms of weight ratio, the composition of the raw materials is: 1 g of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28
1 g, Lactobacillus paracasei YMC1069 1 g, Bifidobacterium bifidum TMC3115
1 gram, 20 grams of resistant dextrin, 10 grams of maltodextrin, 15 grams of corn starch, 20 grams of inulin, 1 gram of stachyose, and 5 grams of elderberry fruit powder.
制备工艺同实施例1。The preparation process is the same as in Example 1.
实施例Example
77
：一种含有乳酸菌的组合物，所用的原料与制备工艺如下：: A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
按重量比计，所述原料的组成为：植物乳杆菌LP45 4克，嗜酸乳杆菌La28
1克，副干酪乳杆菌YMC1069 1克，两歧双歧杆菌TMC3115
1克，抗性糊精30克，麦芽糊精20克，玉米淀粉25克，菊粉30克，水苏糖10克，接骨木莓水果粉10克。In terms of weight ratio, the composition of the raw materials is: 4 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28
1 g, Lactobacillus paracasei YMC1069 1 g, Bifidobacterium bifidum TMC3115
1 gram, 30 grams of resistant dextrin, 20 grams of maltodextrin, 25 grams of corn starch, 30 grams of inulin, 10 grams of stachyose, and 10 grams of elderberry fruit powder.
实施例Example
88
：一种含有乳酸菌的组合物，所用的原料与制备工艺如下：: A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
按重量比计，所述原料的组成为：植物乳杆菌LP45 2.5克，嗜酸乳杆菌La28
0.6克，副干酪乳杆菌YMC1069 0.1克，两歧双歧杆菌TMC3115 0.1克，抗性糊精26.6克，麦芽糊精15.5克，玉米淀粉18.6克，菊粉24.8克，水苏糖5.2克，蔓越莓水果粉6.0克。In terms of weight ratio, the composition of the raw materials is 2.5 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28
0.6 g, Lactobacillus paracasei YMC1069 0.1 g, Bifidobacterium bifidum TMC3115 0.1 g, resistant dextrin 26.6 g, maltodextrin 15.5 g, corn starch 18.6 g, inulin 24.8 g, stachyose 5.2 g, vine 6.0 grams of cranberry fruit powder.
制备工艺同实施例1。The preparation process is the same as in Example 1.
实施例Example
99
：一种含有乳酸菌的组合物，所用的原料与制备工艺如下：: A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
按重量比计，所述原料的组成为：植物乳杆菌LP45 2.5克，嗜酸乳杆菌La28
0.6克，副干酪乳杆菌YMC1069 0.1克，两歧双歧杆菌TMC3115 0.1克，抗性糊精25.7克，麦芽糊精15.0克，玉米淀粉18.0克，菊粉24.0克，水苏糖5.0克，草莓水果粉9.0克。In terms of weight ratio, the composition of the raw materials is 2.5 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28
0.6 g, Lactobacillus paracasei YMC1069 0.1 g, Bifidobacterium bifidum TMC3115 0.1 g, resistant dextrin 25.7 g, maltodextrin 15.0 g, corn starch 18.0 g, inulin 24.0 g, stachyose 5.0 g, strawberry 9.0 grams of fruit powder.
制备工艺同实施例1。The preparation process is the same as in Example 1.
实施例Example
1010
：一种含有乳酸菌的组合物，所用的原料与制备工艺如下：: A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
按重量比计，所述原料的组成为：植物乳杆菌LP45 2.5克，嗜酸乳杆菌La28
0.6克，副干酪乳杆菌YMC1069 0.1克，两歧双歧杆菌TMC3115 0.1克，抗性糊精26.6克，麦芽糊精15.5克，玉米淀粉18.6克，菊粉24.8克，水苏糖5.2克，蔓越莓水果粉6.0克。In terms of weight ratio, the composition of the raw materials is 2.5 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28
0.6 g, Lactobacillus paracasei YMC1069 0.1 g, Bifidobacterium bifidum TMC3115 0.1 g, resistant dextrin 26.6 g, maltodextrin 15.5 g, corn starch 18.6 g, inulin 24.8 g, stachyose 5.2 g, vine 6.0 grams of cranberry fruit powder.
制备工艺同实施例1，利用常规工艺将上述的原料制备成胶囊，每个胶囊含有500mg原料。The preparation process is the same as in Example 1. The above-mentioned raw materials are prepared into capsules using conventional techniques, and each capsule contains 500 mg of raw materials.
实施例Example
1111
：一种含有乳酸菌的组合物，所用的原料与制备工艺如下：: A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
按重量比计，所述原料的组成为：植物乳杆菌LP45 2.5克，嗜酸乳杆菌La28
0.6克，副干酪乳杆菌YMC1069 0.1克，两歧双歧杆菌TMC3115 0.1克，抗性糊精25.7克，麦芽糊精15.0克，玉米淀粉18.0克，菊粉24.0克，水苏糖5.0克，草莓水果粉9.0克。In terms of weight ratio, the composition of the raw materials is 2.5 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28
0.6 g, Lactobacillus paracasei YMC1069 0.1 g, Bifidobacterium bifidum TMC3115 0.1 g, resistant dextrin 25.7 g, maltodextrin 15.0 g, corn starch 18.0 g, inulin 24.0 g, stachyose 5.0 g, strawberry 9.0 grams of fruit powder.
制备工艺同实施例1，利用常规工艺将上述的原料制备成胶囊，每个胶囊含有500mg原料。The preparation process is the same as in Example 1. The above-mentioned raw materials are prepared into capsules using conventional techniques, and each capsule contains 500 mg of raw materials.
实施例Example
1212
：一种含有乳酸菌的组合物，所用的原料与制备工艺如下：: A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
按重量比计，所述原料的组成为：植物乳杆菌LP45 2.5克，嗜酸乳杆菌La28
0.6克，副干酪乳杆菌YMC1069 0.1克，两歧双歧杆菌TMC3115 0.1克，抗性糊精26.6克，麦芽糊精15.5克，玉米淀粉18.6克，菊粉24.8克，水苏糖5.2克，蔓越莓水果粉6.0克。In terms of weight ratio, the composition of the raw materials is 2.5 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28
0.6 g, Lactobacillus paracasei YMC1069 0.1 g, Bifidobacterium bifidum TMC3115 0.1 g, resistant dextrin 26.6 g, maltodextrin 15.5 g, corn starch 18.6 g, inulin 24.8 g, stachyose 5.2 g, vine 6.0 grams of cranberry fruit powder.
制备工艺同实施例1，利用常规工艺将上述的原料制备成片剂，每个片剂含有750mg原料。The preparation process is the same as in Example 1. The above-mentioned raw materials are prepared into tablets using conventional techniques, and each tablet contains 750 mg of raw materials.
实施例Example
1313
：一种含有乳酸菌的组合物，所用的原料与制备工艺如下：: A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
按重量比计，所述原料的组成为：植物乳杆菌LP45 2.5克，嗜酸乳杆菌La28
0.6克，副干酪乳杆菌YMC1069 0.1克，两歧双歧杆菌TMC3115 0.1克，抗性糊精25.7克，麦芽糊精15.0克，玉米淀粉18.0克，菊粉24.0克，水苏糖5.0克，草莓水果粉9.0克。In terms of weight ratio, the composition of the raw materials is 2.5 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28
0.6 g, Lactobacillus paracasei YMC1069 0.1 g, Bifidobacterium bifidum TMC3115 0.1 g, resistant dextrin 25.7 g, maltodextrin 15.0 g, corn starch 18.0 g, inulin 24.0 g, stachyose 5.0 g, strawberry 9.0 grams of fruit powder.
制备工艺同实施例1，利用常规工艺将上述的原料制备成片剂，每个片剂含有750mg原料。The preparation process is the same as in Example 1. The above-mentioned raw materials are prepared into tablets using conventional techniques, and each tablet contains 750 mg of raw materials.
实施例Example
1414
：一种含有乳酸菌的组合物，所用的原料与制备工艺如下：: A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
按重量比计，所述原料的组成为：植物乳杆菌LP45 2.5克，嗜酸乳杆菌La28
0.6克，副干酪乳杆菌YMC1069 0.1克，两歧双歧杆菌TMC3115 0.1克，抗性糊精26.6克，麦芽糊精15.5克，玉米淀粉18.6克，菊粉24.8克，水苏糖5.2克，草莓水果粉6.0克。In terms of weight ratio, the composition of the raw materials is 2.5 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28
0.6g, 0.1g of Lactobacillus paracasei YMC1069, 0.1g of Bifidobacterium bifidum TMC3115, 26.6g of resistant dextrin, 15.5g of maltodextrin, 18.6g of corn starch, 24.8g of inulin, 5.2g of stachyose, strawberry 6.0 grams of fruit powder.
制备工艺同实施例1。The preparation process is the same as in Example 1.
实施例Example
1515
：一种含有乳酸菌的组合物，所用的原料与制备工艺如下：: A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
按重量比计，所述原料的组成为：植物乳杆菌LP45 2.5克，嗜酸乳杆菌La28
0.6克，副干酪乳杆菌YMC1069 0.1克，两歧双歧杆菌TMC3115 0.1克，抗性糊精26.6克，麦芽糊精15.5克，玉米淀粉18.6克，菊粉24.8克，水苏糖5.2克，接骨木莓水果粉6.0克。In terms of weight ratio, the composition of the raw materials is 2.5 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28
0.6g, 0.1g of Lactobacillus paracasei YMC1069, 0.1g of Bifidobacterium bifidum TMC3115, 26.6g of resistant dextrin, 15.5g of maltodextrin, 18.6g of corn starch, 24.8g of inulin, 5.2g of stachyose, elder 6.0 grams of raspberry fruit powder.
制备工艺同实施例1。The preparation process is the same as in Example 1.
实施例Example
1616
：一种含有乳酸菌的组合物，所用的原料与制备工艺如下：: A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
按重量比计，所述原料的组成为：副干酪乳杆菌YMC1069 3.3克，抗性糊精25.7克，麦芽糊精15.0克，玉米淀粉18.0克，草莓水果粉9.0克。In terms of weight ratio, the raw materials consist of 3.3 grams of Lactobacillus paracasei YMC1069, 25.7 grams of resistant dextrin, 15.0 grams of maltodextrin, 18.0 grams of corn starch, and 9.0 grams of strawberry fruit powder.
制备工艺同实施例1。The preparation process is the same as in Example 1.
实施例Example
1717
：一种含有乳酸菌的组合物，所用的原料与制备工艺如下：: A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
按重量比计，所述原料的组成为：副干酪乳杆菌YMC1069 3.3克，抗性糊精25.7克，麦芽糊精15.0克，玉米淀粉18.0克，菊粉24.0克，水苏糖5.0克，草莓水果粉9.0克。In terms of weight ratio, the composition of the raw materials is: 3.3 grams of Lactobacillus paracasei YMC1069, 25.7 grams of resistant dextrin, 15.0 grams of maltodextrin, 18.0 grams of corn starch, 24.0 grams of inulin, 5.0 grams of stachyose, strawberry 9.0 grams of fruit powder.
实施例Example
1818
：一种含有乳酸菌的组合物，所用的原料与制备工艺如下：: A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
按重量比计，所述原料的组成为：植物乳杆菌LP45 2.5克，嗜酸乳杆菌La28
0.6克，副干酪乳杆菌YMC1069 0.1克，两歧双歧杆菌TMC3115 0.1克。In terms of weight ratio, the composition of the raw materials is 2.5 grams of Lactobacillus plantarum LP45 and Lactobacillus acidophilus La28
0.6 grams, 0.1 grams of Lactobacillus paracasei YMC1069, 0.1 grams of Bifidobacterium bifidum TMC3115.
制备工艺同实施例1。The preparation process is the same as in Example 1.
对比实施例Comparative example
11
：一种含有乳酸菌的组合物，所用的原料与制备工艺如下：: A composition containing lactic acid bacteria, the raw materials used and the preparation process are as follows:
按重量比计，所述原料的组成为：抗性糊精26.6克，麦芽糊精15.5克，玉米淀粉18.6克，菊粉24.8克，水苏糖5.2克，接骨木莓水果粉6.0克。In terms of weight ratio, the raw materials consist of 26.6 grams of resistant dextrin, 15.5 grams of maltodextrin, 18.6 grams of corn starch, 24.8 grams of inulin, 5.2 grams of stachyose, and 6.0 grams of elderberry fruit powder.
制备工艺同实施例1。The preparation process is the same as in Example 1.
验证实施例：Verification example:
）本发明组合物对漏油改善和缓解作用) The composition of the present invention improves and relieves oil leakage
1.材料与方法1. Materials and methods
实验单位：山东新时代药业有限公司Experimental unit: Shandong New Times Pharmaceutical Co., Ltd.
动物：昆明种纯系小鼠由鲁南制药集团股份有限公司提供，实验动物合格证批号为: SYXK（鲁）20180008，雌雄各半，3-4周龄，体重在16-20g。Animals: Kunming pure-bred mice are provided by Lunan Pharmaceutical Group Co., Ltd. The batch number of the laboratory animal certificate is: SYXK (鲁)20180008, half male and half, 3-4 weeks old, weighing 16-20g.
实验所涉及的组合物/药物：实施例1、实施例2、实施例3、实施例8、实施例9、实施例16、实施例17、实施例18的组合物，奥利司他胶囊（山东新时代药业有限公司，批号：085190604）。The composition/drug involved in the experiment: the composition of Example 1, Example 2, Example 3, Example 8, Example 9, Example 16, Example 17, and Example 18, orlistat capsule ( Shandong New Times Pharmaceutical Co., Ltd., batch number: 085190604).
实验方法：买回之后饲养一周适应环境，将小鼠随机分组，每组10只，共11组，其中分为A组、B组、C组、D组、E组、F组、G组、H组，连续喂养高脂肪营养饲料（如下配方配制：麦芽糊精20%，酪蛋白22%、猪油22％、蔗糖13％、奶粉7％、花生9％、鸡蛋9％、麻油1％、食盐1％）2日并服用奥利司他药物（服用剂量为=0.78mg/日/灌胃），在服用奥利司他的同时分别服用实施例1、实施例2、实施例3、实施例8、实施例9、实施例16、实施例17、实施例18的产物（服用剂量为=23.4mg/日/灌胃）；a组在服用奥利司他的同时服用生理盐水（服用剂量为=23.4mg/日/灌胃），并连续喂养高脂肪营养饲料；b组服用生理盐水（服用剂量为=23.4mg/日/灌胃）喂养小鼠普通饲料（非高脂肪营养饲料），c组服用生理盐水（服用剂量为=23.4mg/日/灌胃），并连续喂养高脂肪营养饲料。Experimental method: After buying back, raise the mice for one week to adapt to the environment. The mice are randomly divided into groups of 10, a total of 11 groups, which are divided into group A, group B, group C, group D, group E, group F, group G, Group H, continuously fed high-fat nutritious feed (the following formula was formulated: maltodextrin 20%, casein 22%, lard 22%, sucrose 13%, milk powder 7%, peanut 9%, egg 9%, sesame oil 1%, Table salt 1%) for 2 days and take Orlistat (dose = 0.78mg/day/gavage), take Example 1, Example 2, Example 3, and Practice while taking Orlistat The products of Example 8, Example 9, Example 16, Example 17, and Example 18 (dose = 23.4 mg/day/gavage); group a was taking normal saline while taking Orlistat (dose = 23.4mg/day/gavage), and continuously fed high-fat nutrient feed; group b was given normal saline (dose=23.4mg/day/gavage) to feed mice with ordinary feed (non-high-fat nutrient feed), Group c was given normal saline (dose = 23.4 mg/day/gavage), and continuously fed high-fat nutrient feed.
检测指标：连续喂养3日观察各组小鼠的排便粒数、大便是否成型/重量（干重）、后躯是否干净（漏油现象）、体重。后躯干净程度：后躯干净程度从侧方面反应了小鼠的漏油现象，一般而言，小鼠后驱干净5分，比较干净3分，一般1分，差0分。Detection indicators: Observe the number of defecation pellets, whether the stool is formed/weight (dry weight), whether the hindquarters are clean (oil leakage), and body weight of each group of mice after continuous feeding for 3 days. Hindquarters cleanliness: Hindquarters cleanliness reflects the oil leakage of mice from the side. Generally speaking, mice are clean after 5 points, relatively clean 3 points, generally 1 point, 0 points difference.
统计学处理：所有实验数据均以均数±标准差表示， 采用spss19.0软件进行组间显著性t检验。Statistical processing: All experimental data are expressed as mean±standard deviation, and the significance t test between groups was performed using spss19.0 software.
2.结果与分析2. Results and analysis
通过表1可以看出，a组在服用高脂肪饲料的同时与奥利司他服用之后，出现漏油、排便不成形现象，与A-H组相比，具有显著性差异（P＜0.01）；b组与c组相比可以看出，服用奥利司他能够显著的降低体重，减肥效果非常确切，c组大便虽然成型，可能是高脂肪饲料的饲养原因，A-H组在排便粒数、大便重量（干重）、体重上均优于a组，且具有显著性差异（P＜0.01），说明使用本发明的产品与奥利司他进行联合使用与单用奥利司他的效果要好。It can be seen from Table 1 that after taking high-fat feed and orlistat in group a, oil leaks and irregular bowel movements occurred after taking high-fat diet. Compared with group AH, there was a significant difference (P<0.01); b Compared with group c, it can be seen that taking orlistat can significantly reduce weight, and the weight loss effect is very accurate. Although the stool of group c is formed, it may be the reason for feeding high-fat diet. The number of stools and weight of stool in group AH Both (dry weight) and body weight are better than group a, and there is a significant difference (P<0.01), indicating that the product of the present invention and orlistat are used in combination and orlistat alone has better effects.
）本发明组合物对恶唑酮结肠炎小鼠模型的改善和缓解作用) Improving and relieving effects of the composition of the present invention on a mouse model of oxazolone colitis
结肠炎在临床上表现出疼痛、腹胀、腹泻等现象，因此本实验通过构建小鼠结肠炎动物模型实验来验证本发明实施例各种组合物的作用，并进行相关的药效学分析。具体如下：Colitis is clinically manifested as pain, abdominal distension, diarrhea and other phenomena. Therefore, this experiment verified the effects of various compositions of the embodiments of the present invention by constructing a mouse colitis animal model experiment, and conducted related pharmacodynamic analysis. details as follows:
1.材料与方法1. Materials and methods
实验单位：山东新时代药业有限公司Experimental unit: Shandong New Times Pharmaceutical Co., Ltd.
动物：昆明种纯系小鼠由鲁南制药集团股份有限公司提供，实验动物合格证批号为: SYXK（鲁） 2018 0008，雌雄各半，3-4周龄，体重在16-20g。Animals: Kunming pure-bred mice are provided by Lunan Pharmaceutical Group Co., Ltd. The batch number of the laboratory animal certificate is: SYXK (鲁) 2018 0008, half male and half male, 3-4 weeks old, weighing 16-20g.
实验所涉及的组合物/药物：实施例1、实施例2、实施例3、实施例8、实施例9、实施例16、实施例17、实施例18的产物，奥利司他胶囊（山东新时代药业有限公司，批号：085190604），肠炎宁片（江西天施康弋阳制药有限公司）。The composition/drug involved in the experiment: Example 1, Example 2, Example 3, Example 8, Example 9, Example 16, Example 17, Example 18 Products, Orlistat Capsule (Shandong New Times Pharmaceutical Co., Ltd., batch number: 085190604), Changyanning tablets (Jiangxi Tianshi Kang Yiyang Pharmaceutical Co., Ltd.).
动物建模方法：涂搽恶唑酮后小鼠局部皮肤出现红肿，5天后再次灌肠给予小剂量恶唑酮小鼠很快就出现肠道炎症，小鼠结肠炎模型建立。具体为买回之后饲养一周适应环境，将小鼠随机分组，每组10只，共10组，分为A组、B组、C组、D组、E组、F组、G组，以上昆明小鼠肌肉注射速眠新麻醉，腹部皮肤剃毛（1.5cm×1.5cm），皮肤涂搽0.2ml 3%恶唑酮（溶解于100%乙醇中）1天后重复涂搽1次，5天后将直径2mm的硅胶管从肛门插入小鼠肠道深约4cm，注入0.15ml恶唑酮（溶解于50%的乙醇中），72h之后小鼠建模完成。另外取10只小鼠腹部皮肤剃毛（1.5cm×1.5cm），涂抹生理盐水，5天后将直径2mm的硅胶管从肛门插入小鼠肠道深约4cm，注入0.15ml生理盐水。Animal modeling method: After applying oxazolone, the local skin of the mice appeared red and swollen. After 5 days, the mice were given a small dose of oxazolone again by enema, and the mice quickly developed intestinal inflammation, and the mouse colitis model was established. Specifically, the mice were reared for a week to adapt to the environment after the purchase, and the mice were randomly divided into groups of 10 each, a total of 10 groups, divided into group A, group B, group C, group D, group E, group F, group G, above Kunming Mice were injected with Sumianxin anesthesia by intramuscular injection, the abdominal skin was shaved (1.5cm×1.5cm), and 0.2ml of 3% oxazolone (dissolved in 100% ethanol) was applied to the skin after 1 day. Repeat the application once after 5 days. A 2mm diameter silicone tube was inserted into the mouse intestine from the anus to a depth of about 4cm, and 0.15ml of oxazolone (dissolved in 50% ethanol) was injected. After 72 hours, the mouse modeling was completed. In addition, the abdominal skin of 10 mice was shaved (1.5cm×1.5cm), and normal saline was applied. After 5 days, a silicone tube with a diameter of 2mm was inserted into the mouse’s intestine from the anus to a depth of about 4cm, and 0.15ml of normal saline was injected.
实验方法：A组、B组、C组、D组、E组、F组、G组、H组，分别服用实施例1、实施例2、实施例3、实施例8、实施例9、实施例16、实施例17、实施例18的产物（服用剂量为=23.4mg/日/灌胃）；a组服用肠炎宁片（给药剂量：9.8mg/日/灌胃）连续给药4天，b组服用淀粉（剂量为=23.4mg/日/灌胃），c组为假手术组，5天之后观察治疗结果。Experimental method: Group A, Group B, Group C, Group D, Group E, Group F, Group G, Group H, respectively take Example 1, Example 2, Example 3, Example 8, Example 9, and implement The products of Example 16, Example 17, and Example 18 (dose = 23.4 mg/day/gavage); group a took Changyanning tablets (dose: 9.8 mg/day/gavage) for 4 consecutive days , Group b took starch (dose=23.4mg/day/gavage), group c was sham operation group, and the treatment results were observed after 5 days.
检测指标：腹泻和疼痛。结肠炎的最明显的表现在于腹泻，即大便的次数，是最能直观反映结肠炎的结果，本发明试验统计了小鼠24小时内的大便次数；结肠炎的另一个表征就是疼痛，发明人通过在8h内观察小鼠身体扭转次数，小鼠扭转半圈或者大于半圈为一次。体重变化（5天之后称量体重-实验前的体重），各组检测指标测量结果见表2。Detection indicators: diarrhea and pain. The most obvious manifestation of colitis is diarrhea, that is, the number of stools, which is the most intuitive result of colitis. The experiment of the present invention counts the number of stools in mice within 24 hours; another sign of colitis is pain, the inventor By observing the number of twists of the mouse body within 8 hours, the mouse twists half a circle or more than half a circle once. Body weight change (weigh weight after 5 days-weight before experiment), the test results of each group are shown in Table 2.
统计学处理：所有实验数据均以均数±标准差表示， 采用spss19.0软件进行组间显著性t检验。Statistical processing: All experimental data are expressed as mean±standard deviation, and the significance t test between groups was performed using spss19.0 software.
由表2结果显示小鼠体重、大便次数和身体扭转次数，由b组与b组相比可以看出，模型造模成功。而A组、B组、C组、D组、E组、F组、G组、H组均可非常明显起到治疗的作用，主要表现为显著提高体重、减少大便次数和疼痛次数，但是C组、D组、E组的整体效果优于A组、B组、E组、F组、H组，这可能是原料重量份的变化带来的效果差异。其中大便次数、疼痛A组、B组、C组、D组、E组、F组、G组、H组与a组相比具有显著性差异，这表明本发明的组合物效果确切，适合推广应用。The results in Table 2 show the weight of the mice, the number of stools and the number of body torsions. The comparison between group b and group b shows that the model was successfully modeled. And group A, group B, group C, group D, group E, group F, group G, and group H can all play a very obvious role in treatment, which is mainly manifested as a significant increase in weight, reduction of stool frequency and pain frequency, but C The overall effect of group, D group, and E group is better than that of group A, group B, group E, group F, and group H, which may be the effect difference caused by the change of raw material weight. Among them, stool frequency, pain group A, group B, group C, group D, group E, group F, group G, and group H have significant differences compared with group a, which indicates that the composition of the present invention has a definite effect and is suitable for promotion. application.
）人体试验) Human test
根据自愿的原则，选取鲁南制药集团股份有限公司在职员工110人，男女各半，每组10人，分成11组，各组之间无体重、年龄、健康状态等差异，然后进行人体口感度、气味、漏油、排气减少、排便顺畅、腹痛、腹鸣、腹胀的试验。According to the principle of voluntary, 110 employees of Lunan Pharmaceutical Group Co., Ltd. are selected, male and female, 10 people in each group, divided into 11 groups, and there are no differences in weight, age, health status, etc. between the groups, and then the body taste is measured. , Smell, oil leakage, reduced exhaust, smooth defecation, abdominal pain, abdominal pain, abdominal distension test.
实验产品：实施例3、实施例8、实施例9、实施例14、实施例15、实施例16、实施例17、实施例18、对比实施例1、奥利司他胶囊（山东新时代药业有限公司，规格：100mg，生产批号：085190604-085190607）Experimental products: Example 3, Example 8, Example 9, Example 14, Example 15, Example 16, Example 17, Example 18, Comparative Example 1, Orlistat Capsule (Shandong New Times Medicine Industry Co., Ltd., specification: 100mg, production batch number: 085190604-085190607)
入选标准：体重指数（BMI）在24以上，单独服用舒尔佳1-2天，出现排油且持续1-2天。Inclusion criteria: Body mass index (BMI) above 24, taking Shuerga alone for 1-2 days, oil discharge occurs and lasts for 1-2 days.
方法：在山东新时代药业有限公司统一用高脂肪、高能量餐（中午、下午）连续7天，同时服用奥利司他胶囊1粒，饭后分别服用实施例3、实施例8、实施例9、对比实施例1、实施例14、实施例15、实施例16、实施例17、实施例18产品各9克，对照组给予9克淀粉。联合服用5-6天，一个周期共7天。Method: In Shandong New Times Pharmaceutical Co., Ltd. uniform high-fat, high-energy meals (noon, afternoon) for 7 consecutive days, while taking 1 capsule of orlistat, respectively taking Example 3, Example 8, and implementation after meals The products of Example 9, Comparative Example 1, Example 14, Example 15, Example 16, Example 17, and Example 18 were each 9 grams, and the control group was given 9 grams of starch. Take it in combination for 5-6 days, a total of 7 days in a cycle.
检测指标：Detection Indicator:
1）口感程度：服用本发明组合物的口感满意度：非常满意10分，满意7分，一般3分，差1分。1) Degree of mouthfeel: The mouthfeel satisfaction of taking the composition of the present invention: very satisfied 10 points, satisfactory 7 points, general 3 points, and 1 point difference.
2）漏油：矢气时漏油减少程度：非常满意10分，满意7分，一般3分，差1分。2) Oil leakage: The degree of oil leakage reduction when the air is in the air: 10 points for very satisfactory, 7 points for satisfaction, 3 points for general, 1 point for difference.
3）气味：服用本发明组合物的清香程度：非常满意10分，满意7分，一般3分，差1分。3) Smell: the degree of fragrance of the composition of the present invention: very satisfactory 10 points, satisfactory 7 points, general 3 points, 1 point difference.
4）排气减少：排气减少程度：非常满意10分，满意7分，一般3分，差1分。4) Exhaust reduction: Exhaust reduction degree: very satisfactory 10 points, satisfactory 7 points, general 3 points, 1 point difference.
5）排便顺畅：非常满意10分，满意7分，一般3分，差1分。5) Smooth defecation: 10 points for very satisfied, 7 points for satisfaction, 3 points generally, 1 point difference.
6）腹痛、腹鸣、腹胀：腹痛、腹鸣、腹胀减轻程度非常满意10分，满意7分，一般3分，差1分。6) Abdominal pain, abdominal ringing, and abdominal distension: the degree of abdominal pain, abdominal ringing, and abdominal distension is very satisfactory 10 points, satisfactory 7 points, general 3 points, 1 point difference.
结果：对最终的分数进行汇总并采用spss19.0进行统计分析。Results: Summarize the final scores and use spss19.0 for statistical analysis.
从表3可以看出，添加水果粉的口感程度和气味，更容易被接受，但是同样能够解决漏油的问题；对比实施例以及对照组发现，在口感等方面有的与本发明实施例相同，有的是比较差的，例如对比实施例1虽然气味、口感与实施例相同，但是在在漏油的解决上与本发明相比具有显著性差异。It can be seen from Table 3 that the taste and smell of the added fruit powder is more acceptable, but it can also solve the problem of oil leakage; the comparative example and the control group found that some aspects of the taste are the same as those of the embodiment of the present invention. Some are relatively inferior. For example, although the odor and taste of Comparative Example 1 are the same as those of the Examples, there are significant differences in the solution of oil leakage compared with the present invention.
从表4可以看出，经过人体试验，本发明组合物与奥利司他药物一起应用时，可明显减少排气，使得排便过程更加顺畅，同时腹痛、腹鸣、腹胀的现象也得到了有效的缓解和改善。 It can be seen from Table 4 that after human tests, when the composition of the present invention is used together with the orlistat drug, it can significantly reduce exhaust gas and make the defecation process smoother. At the same time, the phenomenon of abdominal pain, abdominal pain, and abdominal distension is also effective. Relief and improvement.
）本发明组合物的指标测定) Index determination of the composition of the present invention
为满足消费者的需求，对本发明的产品进行感官、理化、微生物等各项指标进行检测和测定，具体如下：In order to meet the needs of consumers, the sensory, physical and chemical, microbiological and other indicators of the product of the present invention are tested and measured, specifically as follows:
感官测定：产品的色泽、气味、状态、以及是否有肉眼可见的外来异物。Sensory measurement: the color, smell, state of the product, and whether there are foreign objects visible to the naked eye.
从表5可以看出，对比实施例3中没有辅料，气味较差，色泽为黄色，杂质也有，可能是因为辅料在掩盖气味以及降解杂质中具有一定的作用。It can be seen from Table 5 that there is no auxiliary material in Comparative Example 3, the smell is poor, the color is yellow, and there are impurities. It may be because the auxiliary material has a certain effect in masking the smell and degrading impurities.
理化指标：水分的检测方法按照GB5009.3-2016之第一法检测，铅的检测方法按照GB5009.12-2017之第一法检测。Physical and chemical indicators: The moisture detection method is in accordance with the first method of GB5009.3-2016, and the lead detection method is in accordance with the first method of GB5009.12-2017.
To
从表6可以看出，各组实施例的含水量在1%以下，显著优于标准要求的7.0以下，对比实施例3中没有辅料，水分较多显著高于本发明实施例。It can be seen from Table 6 that the water content of each group of examples is below 1%, which is significantly better than the standard requirement of 7.0 or less. Comparative Example 3 has no auxiliary materials, and the water content is significantly higher than that of the examples of the present invention.
微生物指标：乳酸菌总数、霉菌等微生物的检测。Microbial indicators: detection of the total number of lactic acid bacteria, molds and other microorganisms.
To
从表7可以看出，乳酸菌总数的测定利用GB4789.35-2016法检测，金黄色葡萄球菌GB4789.10-2016第二法检测，沙门氏菌GB4789.4-2016检测，霉菌GB4789.15-2016第一法检测，大肠杆菌GB4789.3-2016第二法检测。各实施例的菌株含量在200亿以上，符合食品相关的要求。It can be seen from Table 7 that the determination of the total number of lactic acid bacteria uses the GB4789.35-2016 method to detect, the Staphylococcus aureus GB4789.10-2016 the second method, the Salmonella GB4789.4-2016, and the mold GB4789.15-2016 first Method detection, E. coli GB4789.3-2016 second method detection. The strain content of each example is more than 20 billion, which meets food-related requirements.
Claims (23)
- 一种乳酸菌的菌株，其特征在于，所述菌株至少包含一种选自植物乳杆菌LP45、嗜酸乳杆菌La28、副干酪乳杆菌YMC1069、两歧双歧杆菌TMC3115。A strain of lactic acid bacteria, characterized in that the strain comprises at least one selected from the group consisting of Lactobacillus plantarum LP45, Lactobacillus acidophilus La28, Lactobacillus paracasei YMC1069, and Bifidobacterium bifidum TMC3115.
- 如权利要求1所述的菌株，其特征在于，按重量比计，所述的植物乳杆菌LP45为 0.1-10份，所述的嗜酸乳杆菌La28为0.01-10份，所述的副干酪乳杆菌YMC1069为0.01-10份，所述的两歧双歧杆菌TMC3115为0.01-10份。The strain of claim 1, wherein, by weight ratio, the Lactobacillus plantarum LP45 is 0.1-10 parts, the Lactobacillus acidophilus La28 is 0.01-10 parts, and the accessory cheese The content of Lactobacillus YMC1069 is 0.01-10 parts, and the content of Bifidobacterium bifidum TMC3115 is 0.01-10 parts.
- 如权利要求1所述的菌株，其特征在于，所述菌株至少包含二种选自植物乳杆菌LP45、嗜酸乳杆菌La28、副干酪乳杆菌YMC1069、两歧双歧杆菌TMC3115。The strain according to claim 1, wherein the strain comprises at least two species selected from the group consisting of Lactobacillus plantarum LP45, Lactobacillus acidophilus La28, Lactobacillus paracasei YMC1069, and Bifidobacterium bifidum TMC3115.
- 如权利要求1所述的菌株，其特征在于，所述菌株至少包含三种选自植物乳杆菌LP45、嗜酸乳杆菌La28、副干酪乳杆菌YMC1069、两歧双歧杆菌TMC3115。The strain according to claim 1, wherein the strain comprises at least three selected from the group consisting of Lactobacillus plantarum LP45, Lactobacillus acidophilus La28, Lactobacillus paracasei YMC1069, and Bifidobacterium bifidum TMC3115.
- 如权利要求1所述的菌株，其特征在于，所述菌株包含植物乳杆菌LP45、嗜酸乳杆菌La28、副干酪乳杆菌YMC1069、两歧双歧杆菌TMC3115。The strain according to claim 1, wherein the strain comprises Lactobacillus plantarum LP45, Lactobacillus acidophilus La28, Lactobacillus paracasei YMC1069, and Bifidobacterium bifidum TMC3115.
- 一种组合物A，其特征在于，所述的组合物含有以下成分A composition A, characterized in that the composition contains the following ingredientsa）含有如权利要求1-5任一项所述的菌株；和a) Contains the strain according to any one of claims 1-5; andb）菊粉、水苏糖中的一种或两种；和/或b) One or two of inulin and stachyose; and/orc）粉剂、粘合剂中的任意一种或者二种。c) Any one or two of powders and adhesives.
- 如权利要求6所述的组合物A，其特征在于，所述粉剂选自淀粉、糊精、调味剂、水果粉、植物提取物以及食品上的添加剂中的任意一种或两种以上组合；所述粘合剂选自玉米淀粉、小麦淀粉、大豆淀粉以及食品上可接受的粘合剂的任意一种。The composition A according to claim 6, wherein the powder is selected from any one or a combination of two or more of starch, dextrin, flavoring agent, fruit powder, plant extract, and food additives; The binder is selected from any one of corn starch, wheat starch, soybean starch, and food-acceptable binders.
- 如权利要求7所述的组合物A，其特征在于，以重量用量比计，所述粉剂选自抗性糊精15-35份，麦芽糊精10-30份，菊粉15-40份，水苏糖1-10份，所述的粘合剂玉米淀粉10-30份。The composition A according to claim 7, wherein the powder is selected from 15-35 parts of resistant dextrin, 10-30 parts of maltodextrin, 15-40 parts of inulin, based on the weight ratio. 1-10 parts of stachyose, 10-30 parts of the said binder corn starch.
- 如权利要求8所述的组合物A，其特征在于，以重量用量比计，所述组合物A的组成为：植物乳杆菌2.5份，嗜酸乳杆菌0.6份，副干酪乳杆菌0.1份，两歧双歧杆菌0.1份，抗性糊精28.34份，麦芽糊精16.54份，玉米淀粉19.85份，菊粉26.46份，水苏糖5.51份。8. The composition A of claim 8, wherein the composition A is composed of 2.5 parts of Lactobacillus plantarum, 0.6 part of Lactobacillus acidophilus, and 0.1 part of Lactobacillus paracasei in terms of weight ratio. 0.1 part of Bifidobacterium bifidum, 28.34 parts of resistant dextrin, 16.54 parts of maltodextrin, 19.85 parts of corn starch, 26.46 parts of inulin, 5.51 parts of stachyose.
- 如权利要求7所述的组合物A，其特征在于，所述水果粉选自柳橙水果粉、接骨木莓水果粉、蔓越莓水果粉、草莓水果粉中的一种或两种以上的组合物。The composition A of claim 7, wherein the fruit powder is selected from one or more of orange fruit powder, elderberry fruit powder, cranberry fruit powder, and strawberry fruit powder. combination.
- 如权利要求10所述的组合物A，其特征在于，按重量比计，所述组合物含有：植物乳杆菌LP45 1-4份，嗜酸乳杆菌La28 0-1份，副干酪乳杆菌YMC1069 0-1份，两歧双歧杆菌TMC3115 0-1份，抗性糊精20-30份，麦芽糊精10-20份，玉米淀粉15-25份，菊粉20-30份，水苏糖1-10份，水果粉5-10份；The composition A according to claim 10, wherein, by weight ratio, the composition contains 1-4 parts of Lactobacillus plantarum LP45, Lactobacillus acidophilus La28 0-1 parts, and Lactobacillus paracasei YMC1069 0-1 parts, Bifidobacterium bifidum TMC3115 0-1 parts, resistant dextrin 20-30 parts, maltodextrin 10-20 parts, corn starch 15-25 parts, inulin 20-30 parts, stachyose 1-10 servings, 5-10 servings of fruit powder;优选为：所述组合物A含有：植物乳杆菌LP45 2.5份，嗜酸乳杆菌La28 0.6份，副干酪乳杆菌YMC1069 0.1份，两歧双歧杆菌TMC3115 0.1份，抗性糊精26.6份，麦芽糊精15.5份，玉米淀粉18.6份，菊粉24.8份，水苏糖5.2份，水果粉6.0份；或所述组合物A含有：植物乳杆菌LP45 2.5份，嗜酸乳杆菌La28 0.6份，副干酪乳杆菌YMC1069 0.1份，两歧双歧杆菌TMC3115 0.1份，抗性糊精25.7份，麦芽糊精15.0份，玉米淀粉18.0份，菊粉24.0份，水苏糖5.0份，水果粉9.0份。Preferably, the composition A contains 2.5 parts of Lactobacillus plantarum LP45, 0.6 parts of Lactobacillus acidophilus La28, 0.1 part of Lactobacillus paracasei YMC1069, 0.1 part of Bifidobacterium bifidobacterium TMC3115, 26.6 parts of resistant dextrin, malt 15.5 parts of dextrin, 18.6 parts of corn starch, 24.8 parts of inulin, 5.2 parts of stachyose, 6.0 parts of fruit powder; or the composition A contains: 2.5 parts of Lactobacillus plantarum LP45, 0.6 parts of Lactobacillus acidophilus La28, vice 0.1 part of Lactobacillus casei YMC1069, 0.1 part of Bifidobacterium bifidum TMC3115, 25.7 parts of resistant dextrin, 15.0 parts of maltodextrin, 18.0 parts of corn starch, 24.0 parts of inulin, 5.0 parts of stachyose, and 9.0 parts of fruit powder.
- 如权利要求6-11任一项所述的组合物A，其特征在于，组合物A是食品。The composition A according to any one of claims 6-11, wherein the composition A is a food.
- 一种即食型乳酸菌，所述即食型乳酸菌含权利要求1-5任一项所述的菌株或6-11任一项所述的组合物A。An instant lactic acid bacteria comprising the strain according to any one of claims 1-5 or the composition A according to any one of 6-11.
- 一种组合物B，其特征在于，所述的组合物B包含：A composition B, characterized in that the composition B comprises:a）即食型乳酸菌；和a) Ready-to-eat lactic acid bacteria; andb）与奥利司他、新利司他、碳酸氢钠、氢氧化铝、铝碳酸镁、阿莫西林、伊立替康、异烟肼、利福平、利福喷汀、氟尿嘧啶类抗肿瘤药物任意一种制备成组合物联合使用或其任意一种联合使用。b) Anti-tumor with orlistat, neolistat, sodium bicarbonate, aluminum hydroxide, hydrotalcite, amoxicillin, irinotecan, isoniazid, rifampicin, rifapentine, fluorouracil Any one of the drugs is prepared into a composition for combined use or any one of them is combined for use.
- 如权利要求1至14中任一项所述的组合物，其特征在于，所述的组合物每g干重包括至少10 6至10 12CFU细菌/g组合物。 The composition according to any one of claims 1 to 14, wherein the composition comprises at least 10 6 to 10 12 CFU bacteria/g composition per g dry weight.
- 如权利要求1至14中任一项所述的组合物，其特征在于，所述的组合物每g干重包括至少10 8至10 11CFU细菌/g组合物。 114 The composition according to any one of claims, wherein said composition comprises per g dry weight of at least 10 8 to 10 11 CFU of bacteria / g composition.
- 如权利要求1-5所述的菌株在制备用于预防和/或减轻胃肠不适或胃肠疾病的食品中的用途。Use of the strains according to claims 1-5 in the preparation of foods for preventing and/or reducing gastrointestinal discomfort or gastrointestinal diseases.
- 如权利要求1-5所述的菌株在制备用于改善胃肠运动性、改善肠道蠕动和/或降低肠道渗透性的食品产品中的用途。Use of the strains according to claims 1-5 in the preparation of food products for improving gastrointestinal motility, improving intestinal motility and/or reducing intestinal permeability.
- 如权利要求6至14中任一项所述的组合物在制备用于预防和/或减轻胃肠不适或胃肠疾病的药品中的用途。Use of the composition according to any one of claims 6 to 14 in the preparation of a medicine for preventing and/or reducing gastrointestinal discomfort or gastrointestinal disease.
- 如权利要求6至14中任一项所述的组合物在制备用于改善胃肠运动性、改善肠道蠕动和/或降低肠道渗透性的药品中的用途。Use of the composition according to any one of claims 6 to 14 in the preparation of a medicine for improving gastrointestinal motility, improving intestinal motility and/or reducing intestinal permeability.
- 一种含1-5任一项所述的菌株或含6-14任一项所述乳酸菌的组合物在制备改善漏油、腹痛、腹胀、腹泻、便秘、改善肠道微环境食品中的应用。Application of a composition containing the strain described in any one of 1-5 or the lactic acid bacteria described in any one of 6-14 in the preparation of foods for improving oil leakage, abdominal pain, bloating, diarrhea, constipation, and improving intestinal microenvironment .
- 一种含有1-5所述的菌株或含6-14所述乳酸菌的组合物制剂产品，其特征在于，所述的制剂产品选自片剂、胶囊剂、颗粒剂、粉剂、丸剂、口服液、软胶囊中的任意一种。A composition preparation product containing the strain described in 1-5 or the lactic acid bacteria described in 6-14, characterized in that the preparation product is selected from the group consisting of tablets, capsules, granules, powders, pills, oral liquids Any one of soft capsules.
- 一种制备权利要求6-13任一项所述组合物A的方法，其特征在于，由以下任意一种方法制备：A method for preparing the composition A according to any one of claims 6-13, characterized in that it is prepared by any one of the following methods:a、取处方量的植物乳杆菌、嗜酸乳杆菌、副干酪乳杆菌、两歧双歧杆菌与抗性糊精、麦芽糊精、玉米淀粉、菊粉、水苏糖、水果粉混合均匀成菌粉，装袋即得；a. Take the prescribed amount of Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus paracasei, Bifidobacterium bifidum and resistant dextrin, maltodextrin, corn starch, inulin, stachyose, and fruit powder and mix them evenly. Bacterial powder, ready to bag;b、b.（1）取处方量的玉米淀粉制备成粘合剂，取处方量的植物乳杆菌、嗜酸乳杆菌、副干酪乳杆菌、两歧双歧杆菌混合均匀成菌粉，备用；(1) Take prescription amount of corn starch to prepare adhesive, take prescription amount of Lactobacillus plantarum, Lactobacillus acidophilus, Lactobacillus paracasei, and Bifidobacterium bifidum and mix them to form a bacterial powder for use;（2）取处方量的抗性糊精、麦芽糊精、菊粉、水苏糖、水果粉搅拌混匀制备成混合物；喷粘合剂造粒，灭菌，过筛，再与菌粉混合，即得。(2) Take the prescribed amount of resistant dextrin, maltodextrin, inulin, stachyose, and fruit powder to prepare a mixture; spray the adhesive to granulate, sterilize, sieving, and then mix with the bacterial powder , That is.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910973576.9 | 2019-10-14 | ||
| CN201910973576.9A CN112716982B (en) | 2019-10-14 | 2019-10-14 | Lactic acid bacteria-containing composition and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021073197A1 true WO2021073197A1 (en) | 2021-04-22 |
Family
ID=75538325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2020/105229 WO2021073197A1 (en) | 2019-10-14 | 2020-07-28 | Composition containing lactic acid bacteria and use thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (2) | CN112716982B (en) |
| WO (1) | WO2021073197A1 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113712200A (en) * | 2021-08-04 | 2021-11-30 | 上海楷达生物科技有限公司 | Composition for improving cardiopulmonary stress and promoting exercise recovery |
| CN114540235A (en) * | 2022-03-04 | 2022-05-27 | 中国海洋大学 | Method for inducing lactic acid bacteria dormant state and application thereof |
| CN115181695A (en) * | 2022-06-27 | 2022-10-14 | 广东粤港澳大湾区国家纳米科技创新研究院 | Lactobacillus plantarum5b4m2 and application thereof |
| CN115671132A (en) * | 2020-06-01 | 2023-02-03 | 山东新时代药业有限公司 | Composition of probiotics and prebiotics and application thereof |
| CN116235955A (en) * | 2023-05-12 | 2023-06-09 | 北京新浠芮生物技术有限公司 | Composition with functions of balancing immunity and protecting liver |
| CN116262125A (en) * | 2023-01-19 | 2023-06-16 | 哈尔滨美华生物技术股份有限公司 | Lactobacillus casei L7-13 for protecting gastric mucosa and relieving gastritis and application thereof |
| CN116726054A (en) * | 2022-12-05 | 2023-09-12 | 山东新时代药业有限公司 | Instant probiotic composition and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107847483A (en) * | 2015-04-30 | 2018-03-27 | 益生菌股份公司 | Antibiotic with particular treatment activity and the Bacillus acidi lactici with identical treatment idicatio with not transferable antibiotic resistance and/or Bifidobacterium at the same associated with apply |
| CN110150669A (en) * | 2019-04-29 | 2019-08-23 | 河北一然生物科技有限公司 | A kind of probiotic composition and its application suitable for patients with diabetes mellitus |
| CN110946913A (en) * | 2019-12-17 | 2020-04-03 | 河北一然生物科技有限公司 | Probiotic composition for relieving constipation and hemorrhoids |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1020123A1 (en) * | 1999-01-18 | 2000-07-19 | Sitia-Yomo S.p.A. | Beverages containing live lactic bacteria |
| CN103642716B (en) * | 2013-11-21 | 2017-02-01 | 河北一然生物科技有限公司 | Lactobacillus plantarum and application thereof |
| CN104630096B (en) * | 2014-12-16 | 2016-08-24 | 河北一然生物科技有限公司 | There is bifidobacterium bifidum TMC3115 and the application thereof of suppression adipose cell |
| CN106011006A (en) * | 2016-06-01 | 2016-10-12 | 河北然生物科技有限公司 | Lactobacillus acidophilus La28 with immunoregulation function and allergy-resisting function and applications of lactobacillus acidophilus La28 |
| CN107050062A (en) * | 2016-11-08 | 2017-08-18 | 江西益盟科技有限公司 | Treat lactic bacteria composition of constipation and preparation method thereof |
| CN106860483A (en) * | 2017-01-06 | 2017-06-20 | 家家乐购（北京）科技有限公司 | Probiotics complex composition and application containing Bifidobacterium and lactobacillus acidophilus |
| CN109938249B (en) * | 2017-12-21 | 2022-06-10 | 中粮营养健康研究院有限公司 | Rice protein composition |
| CN108004189B (en) * | 2018-01-18 | 2021-07-27 | 北京科拓恒通生物技术股份有限公司 | Composite probiotic lactic acid bacteria powder and preparation method and application thereof |
| CN110179120A (en) * | 2018-02-22 | 2019-08-30 | 杨涵 | A kind of compound diet of probiotics pectase corn peptide improving immunity lower hyperlipidemia, hypertension, hyperglycemia |
-
2019
- 2019-10-14 CN CN201910973576.9A patent/CN112716982B/en active Active
- 2019-10-14 CN CN202210665268.1A patent/CN115074274B/en active Active
-
2020
- 2020-07-28 WO PCT/CN2020/105229 patent/WO2021073197A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107847483A (en) * | 2015-04-30 | 2018-03-27 | 益生菌股份公司 | Antibiotic with particular treatment activity and the Bacillus acidi lactici with identical treatment idicatio with not transferable antibiotic resistance and/or Bifidobacterium at the same associated with apply |
| CN110150669A (en) * | 2019-04-29 | 2019-08-23 | 河北一然生物科技有限公司 | A kind of probiotic composition and its application suitable for patients with diabetes mellitus |
| CN110946913A (en) * | 2019-12-17 | 2020-04-03 | 河北一然生物科技有限公司 | Probiotic composition for relieving constipation and hemorrhoids |
Non-Patent Citations (3)
| Title |
|---|
| ZANG, KAILI ET AL.: "Probiotics Modulate the Structure and Abundance of Gut Mircrobiota in Populations with Intestinal Diseases", FOOD SCIENCE, vol. 39, no. 13, 15 July 2018 (2018-07-15), pages 133 - 143, XP055803033 * |
| ZANG, KAILI ET AL.: "Progression of the Interaction between Probiotic Proteins and Intestinal Mucosal Immunity", SCIENCE AND TECHNOLOGY OF FOOD INDUSTRY, vol. 39, no. 14, 31 July 2018 (2018-07-31), pages 346 - 351, XP055803051 * |
| ZANG, KAILI ET AL.: "Relationship between Microecologics and the Expression of Short Chain Fatty Acids Synthesis Genes in Key Bacterial Genera in the Regulation of Intestinal Flora Structure in Populations with Constipation and Diarrhea", FOOD SCIENCE, vol. 39, no. 05, 15 March 2018 (2018-03-15), pages 155 - 165, XP055803048 * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115671132B (en) * | 2020-06-01 | 2024-03-15 | 山东新时代药业有限公司 | Composition of probiotics and prebiotics and application thereof |
| CN115671132A (en) * | 2020-06-01 | 2023-02-03 | 山东新时代药业有限公司 | Composition of probiotics and prebiotics and application thereof |
| CN113712200A (en) * | 2021-08-04 | 2021-11-30 | 上海楷达生物科技有限公司 | Composition for improving cardiopulmonary stress and promoting exercise recovery |
| CN114540235A (en) * | 2022-03-04 | 2022-05-27 | 中国海洋大学 | Method for inducing lactic acid bacteria dormant state and application thereof |
| CN114540235B (en) * | 2022-03-04 | 2023-10-31 | 中国海洋大学 | Method for inducing lactic acid bacteria to sleep and application thereof |
| CN115181695B (en) * | 2022-06-27 | 2023-08-29 | 广东粤港澳大湾区国家纳米科技创新研究院 | Lactobacillus plantarum5b4m2 and application thereof |
| CN115181695A (en) * | 2022-06-27 | 2022-10-14 | 广东粤港澳大湾区国家纳米科技创新研究院 | Lactobacillus plantarum5b4m2 and application thereof |
| CN116726054A (en) * | 2022-12-05 | 2023-09-12 | 山东新时代药业有限公司 | Instant probiotic composition and preparation method and application thereof |
| CN116726054B (en) * | 2022-12-05 | 2024-03-26 | 山东新时代药业有限公司 | Instant probiotic composition and preparation method and application thereof |
| CN116262125A (en) * | 2023-01-19 | 2023-06-16 | 哈尔滨美华生物技术股份有限公司 | Lactobacillus casei L7-13 for protecting gastric mucosa and relieving gastritis and application thereof |
| CN116262125B (en) * | 2023-01-19 | 2023-11-14 | 哈尔滨美华生物技术股份有限公司 | Lactobacillus casei L7-13 for protecting gastric mucosa and relieving gastritis and application thereof |
| CN116235955A (en) * | 2023-05-12 | 2023-06-09 | 北京新浠芮生物技术有限公司 | Composition with functions of balancing immunity and protecting liver |
| CN116235955B (en) * | 2023-05-12 | 2023-12-29 | 北京新浠芮生物技术有限公司 | Composition with functions of balancing immunity and protecting liver |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115074274B (en) | 2023-04-18 |
| CN112716982B (en) | 2022-09-13 |
| CN112716982A (en) | 2021-04-30 |
| CN115074274A (en) | 2022-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021073197A1 (en) | Composition containing lactic acid bacteria and use thereof | |
| KR101911205B1 (en) | Composition for defecation inducement and diet and producing method thereof | |
| AU2005294369A1 (en) | Synbiotics | |
| CN105685970A (en) | Compound nutritious food capable of improving whole digestive tract | |
| AU2019241546B2 (en) | Sleep-promoting composition, and medicinal composition and food and beverage composition using said sleep-promoting composition | |
| WO2017130859A1 (en) | Neuronal cell death inhibitor | |
| WO2016049879A1 (en) | Uses of bacteroides in treatment or prevention of obesity-related diseases | |
| WO2023116227A1 (en) | Microbial combination having weight loss effect and application thereof | |
| CN112955163A (en) | Probiotic combinations for the treatment of inflammatory-related gastrointestinal disorders | |
| CN106974262B (en) | Application of intestinal probiotic bacillus in treating and preventing obesity and related diseases | |
| CN109315769A (en) | It is a kind of for improving the composition and preparation method thereof of human body enteral environment | |
| CN113660941A (en) | Probiotic combinations for the treatment of allergic diseases | |
| CN113750113B (en) | Composition of probiotics and prebiotics and application thereof | |
| Georgieva et al. | Probiotics and immunity | |
| CN107002023B (en) | Use of bacteroides in the treatment or prevention of obesity related diseases | |
| CN107752015A (en) | The composite nutrient food that a kind of all-digestive tract improves | |
| CN107279234A (en) | The biscuit of healthy intestinal health | |
| CN105266162B (en) | A kind of natto capsule health food containing for having whole intestines concurrently and adjusting immunity | |
| CN106889615B (en) | Microelement selenium dietary supplement with function of regulating intestinal flora and application thereof | |
| TWI744028B (en) | Prebiotic composition for promoting growth of clostridium butyricum and uses thereof | |
| CN108157595A (en) | A kind of probiotics and preparation method thereof | |
| CN110279720B (en) | Processed maggot product and application thereof in regulating intestinal flora | |
| JP7266580B2 (en) | Composition for infants for prevention of diseases caused by hyperglycemia after school age | |
| CN111603489A (en) | Microbial inoculum for improving constipation and preparation method thereof | |
| CN106974939B (en) | Application of probiotics of scleritis in treating and preventing obesity and related diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20877195 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20877195 Country of ref document: EP Kind code of ref document: A1 |